T-Lineage Specification and Commitment Requires Constraint of Myeloid Gene Expression Programs by Hes1 by De Obaldia, Maria Elena
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2014
T-Lineage Specification and Commitment
Requires Constraint of Myeloid Gene Expression
Programs by Hes1
Maria Elena De Obaldia
University of Pennsylvania, ellend856@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons,
and the Medical Immunology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1255
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
De Obaldia, Maria Elena, "T-Lineage Specification and Commitment Requires Constraint of Myeloid Gene Expression Programs by
Hes1" (2014). Publicly Accessible Penn Dissertations. 1255.
http://repository.upenn.edu/edissertations/1255
T-Lineage Specification and Commitment Requires Constraint of
Myeloid Gene Expression Programs by Hes1
Abstract
Early thymic progenitors (ETPs) are not committed to the T cell lineage; however, whether ETPs realize
alternative (non T cell) lineage potentials in vivo is not well understood and indeed controversial. Notch
signaling induces T cell lineage gene expression and discourages alternative fate outcomes; however, the
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thymus (Chapter 2) and second, we investigate the mechanisms used to constrain alternative gene expression
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myeloid developmental fates in vivo, since the majority of thymic granulocytes appear to derive from ETPs.
Next, we identified the Notch target and transcriptional repressor Hes1 as an important mechanism that
constrains myeloid gene expression programs in T cell progenitors. Hes1 deficiency in hematopoietic
progenitors severely compromises T cell development; however, this defect can be completely rescued by
deletion of the myeloid regulator C/EBPα. Thus, our findings indicate that ETPs are bona fide myelo-
lymphoid progenitors and establishes the critical importance of constraining myeloid developmental
programs early in T cell development.
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ABSTRACT 
 
T-LINEAGE SPECIFICATION AND COMMITMENT REQUIRES CONSTRAINT OF 
MYELOID GENE EXPRESSION PROGRAMS BY HES1 
Maria Elena De Obaldia 
Avinash Bhandoola 
 
Early thymic progenitors (ETPs) are not committed to the T cell lineage; however, 
whether ETPs realize alternative (non T cell) lineage potentials in vivo is not well 
understood and indeed controversial. Notch signaling induces T cell lineage gene 
expression and discourages alternative fate outcomes; however, the mechanisms by 
which this occurs remain unclear. The work described here provides insight into two 
related questions in the field of early T cell development: first, we address whether ETPs 
adopt alternative fates in the thymus (Chapter 2) and second, we investigate the 
mechanisms used to constrain alternative gene expression programs as progenitors 
commit to the T cell lineage (Chapter 3 and 4). We found that ETPs do in fact access 
myeloid developmental fates in vivo, since the majority of thymic granulocytes appear to 
derive from ETPs. Next, we identified the Notch target and transcriptional repressor 
Hes1 as an important mechanism that constrains myeloid gene expression programs in T 
cell progenitors. Hes1 deficiency in hematopoietic progenitors severely compromises T 
cell development; however, this defect can be completely rescued by deletion of the 
myeloid regulator C/EBPα. Thus, our findings indicate that ETPs are bona fide myelo-
lymphoid progenitors and establishes the critical importance of constraining myeloid 
developmental programs early in T cell development.  
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CHAPTER 1:  INTRODUCTION 
 
 
1.1 Establishment of cell identity 
 
 
Cellular differentiation is loosely defined as the process by which a less 
specialized cell type becomes a more specialized cell type.  As a cell differentiates, it takes 
on new properties, and may change its size, shape, metabolic requirements, and 
responsiveness to external stimuli. These phenotypic changes are driven by changes in 
gene expression. Generally, cellular differentiation is thought to proceed in one 
direction, since gene regulatory mechanisms exist that simultaneously allow new gene 
expression and disallow past gene expression. As stem cells differentiate, they begin to 
express genes characteristic of a particular terminally differentiated cell type and 
progressively lose the ability to access gene expression programs associated with 
alternative cell fates. These processes are referred to as lineage specification and 
commitment, respectively.   Lineage specification entails the positive regulation of genes 
associated with the fate being adopted. It is clear that activation of lineage-specific gene 
expression is not itself sufficient to explain acquisition of a particular cellular identity.   
In order to “choose” one identity, multipotent progenitors, must also “renounce” the 
ability to develop into all other alternative cell types by the process of lineage 
commitment.  
 
A remarkable exception to the unidirectionality of differentiation is the 
phenomenon of “reprogramming” by which introduction of exogenous transcription 
factors effectively “erases” the identity of a terminally differentiated cell, causing it to 
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adopt another fate, possibly via an induced pluripotent stem cell (iPS cell) or 
dedifferentiated progenitor intermediate state.  The 2012 Nobel Prize in Medicine was 
awarded to Shinya Yamanaka and Sir John Gurdon for their work on reprogramming. 
Gurdon first showed in 1962 that somatic cells transferred into enucleated frog eggs 
could be reprogrammed to an embryonic state1. Yamanaka’s group found that four 
transcription factors (Oct4, Sox2, Klf4, and c-Myc) could recapitulate this 
reprogramming process to generate iPS cells2. The identification of these “Yamanaka” 
factors provided support to the idea that just a handful of transcriptional regulators 
could exert powerful, deterministic effects on cell fate. This belief is at the heart of the 
concept of “master regulators” of cell identity, which has become widespread in recent 
years. So-called “master regulators” are transcription factors that are necessary and 
sufficient for the acquisition of lineage identity. Thus, “master regulators” often have the 
ability to both activate lineage-specific gene expression and to repress expression of 
other factors promoting an alternative lineage. The identification and characterization of 
master regulators has traditionally been achieved using gene-specific knockout strategies 
and ectopic expression assays. 
 
Genome-wide studies of gene expression, transcription factor binding, and 
chromatin modifications are leading to a more complete picture of how lineage-specific 
gene expression is achieved. Metazoan gene regulation is thought to depend upon the 
interaction of promoters with enhancers, gene regulatory elements that may be located 
at a distance from the promoters they regulate. It is thought that enhancers are 
especially critical for the activation of lineage-specific gene expression3. Next-generation 
sequencing has revealed that many enhancer elements are marked with a permissive 
chromatin signature: monomethylation of histone H3 lysine (H3K4me1) without 
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trimethylation (H3K4me3)4–6. Enhancer elements may also be identified by evolutionary 
conservation and an abundance of DNAse hypersensitivity sites7.   
 
Enhancers may display either a poised or transcriptionally competent 
configuration after receiving appropriate signals. Poised enhancers are marked by 
repressive (H3K27me3) and activating (H3K4me3) chromatin modifications78. Poised 
enhancers are transcriptionally inactive, but can be rapidly activated when 
differentiation signals are received. The activity of specific enhancers can be determined 
by examining combination of the H3K4me1 mark with histone acetyltransferase (HAT) 
p300 binding or deposition of H3K27ac acetylation marks9–13. Moreover, other factors, 
such as the HATs CBP or SAGAs may regulate activity of enhancer landscapes 
independently of p30014,15. Since H3K4me1 modifications are more broadly distributed 
than p300 binding, it is possible that their deposition precedes that of p30016. 
“Pioneering factors” may deposit H3K4me1 marks on poised chromatin to begin to setup 
an enhancer, where downstream regulators can then bind16,17.  
 
Like gene activation, the process of gene repression relies upon the use of cis-
regulatory elements and sequence-specific DNA binding factors; however, less is known 
about the mechanisms used to achieve target gene repression compared to activation18. 
For example, it is not known how many different types of factors are needed to 
accomplish transcriptional repression; whereas, the transcriptional activation machinery 
is relatively well characterized.  Repressive regulatory elements can be identified by loss 
of histone acetylation, reduced H3k4 methylation, and reduced DNase accessibility due 
to compaction of the nucleosomal array19–21. Because of compaction, repressed elements 
are generally less detectable than neutral DNA elements, creating technical issues that 
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complicate systematic analysis of repression18. The H3K27me3 chromatin modification 
is found to mark some repressed regions, following deposition by the Polycomb 
repressive complex 2 (PRC2); however, it appears that this mark only is placed after 
inhibition of transcription has already occurred22. This temporal issue makes it difficult 
to identify the factors that initially caused repression. It is possible that additional 
chromatin modifications which mark repressed regions remain to be identified. Whereas 
eukaryotic transcriptional activators generally interacting with the core transcriptional 
machinery or through recruitment of chromatin modifying co-activators, it appears that 
repressors largely rely on indirect interactions with co-repressor proteins, and rarely 
modify activity of the core transcriptional machinery23. Since lineage commitment is 
thought to rely heavily on the repression of alternative lineage gene expression, a better 
understanding of repressive mechanisms is needed in order to elucidate lineage 
commitment processes. 
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1.2 Hematopoiesis overview 
 
Hematopoiesis is an excellent model system for the study of cell fate decisions, 
since in many cases progenitor intermediates have been defined by cell surface markers, 
allowing for isolation by fluorescence activated cell sorting (FACS) and the use of single-
cell assays. Models of hematopoietic differentiation may reflect either developmental 
potential (“what cells can do”) or physiological cell fate (“what cells actually do”, 
presumably in vivo). In any case, the complement of developmental potentials possessed 
by a population is presumably a broader category that must encompass the physiological 
cell fates realized by that progenitor cell type. Identification of progenitor-progeny 
relationships in vivo has relied on adoptive transfer of progenitors into irradiated 
animals. Because the cytokine milieu may be altered in the irradiated host, it is necessary 
to validate adoptive transfer studies using genetically based fate-mapping approaches in 
the steady state.  
 
Single cell analyses of developmental potential are often more informative than 
bulk assays, due to heterogeneity within prospectively isolated populations based on 
currently available cell surface markers. The development of single cells can be more 
easily studied and quantified in vitro than in vivo, due to technical limitations. While in 
vitro developmental assays are commonly thought to be more permissive than in vivo 
assays, in that they may allow for detection of potentials that are not necessarily realized 
in vivo; however, the opposite may also be true, since in vitro assays are optimized to 
support development of particular cell types. Thus, particular assays may underrepresent 
the developmental potentials of a particular population. This makes it challenging to 
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detect the full complement of developmental potentials possessed by single cells of a 
particular population.  
 
All cellular components of the blood derive from hematopoietic stem cells (HSCs) 
through a complex process of differentiation. Hematopoiesis proceeds in a hierarchical 
fashion, with primitive HSCs at the apex of the hierarchy (Figure 1-1). Functionally, HSCs 
were identified as single cells able to rescue the entire hematopoietic compartment of a 
lethally irradiated mouse24–27. HSCs reside in the fetal liver (FL) during gestation and in 
the bone marrow (BM) of the adult, and have the unique properties of being pluripotent 
and capable of self-renewal. HSCs are enriched within the BM Lin–Sca1+Kit+ (LSK) 
compartment, since they express high levels of stem cell antigen 1 (Sca1) and the growth 
receptor tyrosine kinase Kit. HSCs may also be purified using SLAM markers CD150 and 
CD48 as CD150+CD48- cells28–31.  HSCs give rise to downstream progenitors, such as 
multipotent progenitors (MPPs), which have lost self-renewal capacity and upregulated 
expression of FMS-related tyrosine kinase 3 (Flt3). As progenitors undergo 
differentiation, the complement of developmental potentials they possess becomes 
“restricted” in a stepwise fashion, until progenitors are generated that are “committed” 
to generate only one terminally differentiated cell lineage.  Lineage commitment is 
induced by both cell intrinsic mechanisms, such as transcription factors and regulatory 
RNAs, as well as extrinsic mechanisms like cytokines, cell-cell interactions, and other 
environmental cues. Since the loss of a given developmental potential may theoretically 
occur in several ways, it follows that cells may commit to a fate via distinct pathways. 
Evidence for such flexibility exists; however, "major" pathways can usually be identified.  
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Historically, mature blood cells have been broadly classified into several major 
groups: megakaryocyte/erythroid, myeloid, and lymphoid lineages. Lymphocytes were 
initially distinguished from myeloid cells based on their relative lack of cytoplasm and 
their enrichment in lymph, lymph nodes, spleen, and thymus. Myeloid cells were 
identified as phagocytic cells with abundant cytoplasm that were enriched in the BM.  In 
most cases, hematopoietic cells develop in the FL of embryos and the BM of the adult, 
with the exception of T cells, which complete their maturation in a specialized organ, the 
thymus. The dichotomy between myeloid and lymphoid lineages gave rise to what is 
commonly known as the “classical model” of hematopoiesis in which there is an early, 
obligate bifurcation between myeloid and lymphoid lineages. The identification of 
common lymphoid progenitors (CLP)32, and later common myeloid progenitors 
(CMP)33,34, in the BM by Irv Weissman’s group represented a major conceptual advance 
in the field of hematopoiesis that provided experimental support for the classical model. 
This discovery of lineage-restricted progenitors downstream of HSCs indicated that 
developmental potentials are lost in a stepwise fashion. 
 
While the classical model has been instrumental for developing our 
understanding of hematopoiesis, its central tenet, the idea that lymphoid and myeloid 
lineages strictly separate upstream of the CLP and CMP, has been challenged. Instead, a 
“revised model” of hematopoiesis suggests that there are multiple alternative 
developmental pathways by which early hematopoietic progenitors undergo lymphoid-
myeloid branching35. Sten Eirik Jacobsen’s group identified lymphoid-primed 
multipotent progenitors (LMPPs) as Flt3hi MPPs, cells which had lost 
megakaryocyte/erythroid (MegE) potential, but retained myeloid and lymphoid 
potentials36. Thus, it was possible that myeloid cells could originate from progenitors 
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with or without MegE potential, CMPs or LMPPs, respectively.  LMPPs are thought to be 
the upstream precursors of CLPs, cells which maintain Flt3 expression, downregulate 
Sca1 and Kit (expressed at high levels on HSCs and LMPPs), and upregulate the 
lymphoid cytokine receptor IL-7Rα.   The process by which multipotent progenitors, 
such as LMPPs differentiate to form lymphoid progenitors is not well understood, and is 
discussed in more detail below.  
 
1.3 Generation of lymphoid progenitors 
 
 
How some descendants of HSCs “decide” to become lymphoid progenitors is not 
well understood, but may involve signals from the BM niche, cytokines, and 
transcription factors such as E2A, Ikaros, Bcl11a, PU.1, STAT5a/b, HOXA9, Satb1, and 
others37–44. Some HSCs may be lymphoid-biased (reviewed in 45). Lymphoid priming in 
HSCs may be important for downstream lymphoid development46.One critical aspect of 
generating CLPs is the attenuation of myeloid potential. It is likely that E-proteins play a 
role in initiating this process in the bone marrow37,47,48. As lymphoid progenitors 
subsequently commit to a specific lymphoid lineage, there are likely to be lineage-specific 
mechanisms to repress and eventually silence myeloid fates. In this thesis, we investigate 
one such lineage-specific mechanism, showing that Hes1 constrains myeloid gene 
expression programs during T cell development in the thymus. Interestingly, Hes1 
appears not to be necessary to attenuate myeloid potential during the generation of BM 
lymphoid progenitors, B cells, or type 2 innate lymphoid cells (ILC2s).   
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E2A is important for the initiation of lymphoid gene expression and the 
generation of BM LMPPs37. Interestingly, E2A protein is not increased in LMPPs 
compared to HSCs37. It may be that the decreased expression of E protein dimerization 
partners (such as TAL1) in LMPPs results in increased availability of E proteins to 
function in homodimeric complexes that activate lymphoid gene expression49. While 
E2A is not required for extinction of MegE potential, it does appear to impact upon 
myeloid versus lineage decisions, since residual LMPPs remaining in E2A-deficient mice 
demonstrate enhanced myeloid cloning efficiency and deregulation of many lymphoid 
genes: Rag1, Il7ra, Dntt, Igh-6, Notch1, CCR9, and Ets137. E2A may promote lymphoid 
gene expression by collaborating with other transcription factors which are expressed in 
LSKs and MPPs, such as PU.1, Ikaros, and Gfi-1, and which do not depend on E2A for 
their expression49. DNA sequences flanking the transcriptional start sites of E2A-
dependent genes were enriched for Ikaros and PU.1 binding sites, providing evidence for 
cooperation of these factors with E2A37. The cytokine receptor Flt3 is thought to be 
upregulated by Ikaros and PU.150–52. Among the E2A-regulated genes noted above are 
several cell-surface receptors: IL-7Rα, Notch1, and CCR9, which confer cells with the 
ability to respond to microenvironmental cues. Signaling downstream of IL7-Rα or 
Notch1 signaling can lead to upregulation of transcription factors important for B cell or 
T cell generation, respectively. 
 
While CLPs are strongly biased to generate lymphocyte progeny, they are not 
absolutely restricted to the lymphoid lineage and display a degree of myeloid/DC 
potential under some conditions53,54. The originally proposed CLP population has been 
shown to be heterogeneous, including B cell specified progenitors, which express Ly6D.  
Ly6D+ CLPs are devoid of myeloid potential, but lack T cell potential in vivo55.  Ly6D+ 
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CLPs appear to have T cell potential in vitro; however, it appears that they do not 
contribute to T cell development in vivo, perhaps because they lack the ability to home to 
the thymus56.  Thus, Ly6D– CLPs and LMPP may contribute to T cell development in the 
thymus, though their relative contributions are unclear. Whether or not CLPs are 
obligate intermediates in the T cell pathway, it is clear that they contribute extensively to 
the development of B cells, NK cells, innate lymphoid cells (ILCs) outside the thymus57–
60.   
1.4 T lymphopoiesis overview 
 
 
T cells complete their maturation in the thymus from circulating BM-derived 
progenitors (Figure 1-2). Thymus settling is a selective process.  Determining the relative 
extent to which CLPs (lymphoid progenitors) and LMPPs (multipotent or myelo-
lymphoid progenitors) contribute to T cell development has been a confusing area of 
investigation, despite intensive study. Both CLPs and LMPPs, but not upstream HSCs, 
are able to rapidly generate T cell progeny following intravenous transfer into irradiated 
recipients; however, only Sca1hiKithi cells resembling HSCs/LMPPs appear to be found in 
the blood61,62. Furthermore, ETPs have more robust T cell reconstitution capacity than 
CLPs, suggesting that ETPs derive from cells more developmentally upstream of CLPs, 
such as LMPPs63. Additionally, several findings suggest that T cell development can 
occur independently of CLPs, since Ikaros-deficient mice lack CLPs, but not ETPs63. 
Indeed, the ETP cell surface phenotype resembles that of LMPPs in that both 
populations express high levels of Kit, and most cells in each population appear to lack 
surface IL-7Rα expression. Thus, the phenotypes of ETPs and LMPPs differ in several 
important ways from the that of CLPs, which express low levels of Kit and are 
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unambiguously IL-7Rα+(ref. 63). Hence, studies probing the identity of thymus settling 
progenitors  (TSPs) have raised questions about the validity of the classical model of 
hematopoiesis by challenging the idea that there is an early, obligate segregation of 
myeloid and lymphoid potentials in the BM64–67. Instead, myelo-lymphoid progenitors 
such as LMPPs (cells more developmentally primitive than CLPs) may be the primary 
progenitors of T cells65.  
 
As thymus settling progenitors (TSP) enter the thymus, strong Notch signals 
initiate the very earliest stages of T cell development: proliferation and generation of 
early thymic progenitors (ETPs)20. ETPs are CD4/CD8 double negative (DN) precursors, 
a subset of the DN1 population, which represent the most primitive progenitors of T cells 
that can be identified in the thymus63,69.    Thymic epithelial cells are specialized to 
support T cell development, because they express high levels of Notch ligands and the 
cytokines Kit ligand and IL-7, which are important for maintenance and proliferation of 
early T cell progenitors. Notch signaling is critical for the generation of T cells, since 
inactivation of Notch1 signaling in bone marrow stem/progenitor cells results in 
abrogation of T cell development70–73.  The critical ligand pair for T cell development was 
identified to be Delta-like ligand 4 (DLL4) (refs. 74,75). Progenitors enter the thymus with 
Notch1 receptor on their surface, which was induced by E-proteins in the BM. The 
expression of Fringe proteins in thymocytes primes them to respond to intrathymic 
Notch ligands76. Notch receptors span the cell membrane, and when the extracellular 
portion of the receptor is bound by ligand, this induces proteolytic cleavage and releases 
the intracellular domain of Notch (ICN), which translocates to the nucleus (Figure 1-3).  
In the nucleus, ICN forms a transcriptional activation complex coupled with the RBP-
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Jk/CSL protein, mastermind-like (MAML), and co-activators, such as p300 in order to 
initiate transcription of Notch target genes77. 
 
Notch signaling launches the T cell program in DN progenitors by upregulating 
the expression of T cell-specific transcription factors, including TCF-1, GATA-3, and 
Bcl11b78. Even once these factors are turned on, continuous Notch signals are required to 
maintain expression of important T-lineage genes79–81. Notch signaling terminates after 
the DN3 stage, indicating that other mechanisms are needed to lock in the T cell fate and 
maintain the core T cell program in mature T cells.  In addition to activating 
transcription factors that initiate T-lineage specification, Notch signaling is thought to be 
critical for the inhibition of alternative fates by upregulating transcriptional repressors, 
such as Hes1 and Bcl-11b. Antagonizing alternative fates is critical, because in addition to 
robust T cell potential, ETPs retain the potential to develop into non-T cell lymphoid 
cells (B cells17,20 and ILCs33/NK cells48), DCs47,50, and, to a degree, myeloid cells53,64,66,82,83. 
The mechanisms by which alternative lineage potentials are constrained are discussed 
further below.  
 
As ETPs progress along the T cell developmental pathway, they proceed through 
a series of intermediate stages that are defined based on the expression of cell surface 
markers described below (also see Figure 1-4).  ETPs proliferate and differentiate to form 
DN2a cells, which maintain the high levels of Kit surface expression characteristic of 
ETPs and which upregulate CD25 (IL-2Rα), which is a Notch target.  DN2a cells initiate 
TCRβ locus rearrangement and express many T-lineage genes, yet they are not yet T-
lineage committed. Activation of an Lck-GFP transgene marks the onset of T-lineage 
commitment at the late DN2a stage, coincident with Bcl-11b upregulation84. The process 
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of T-lineage commitment is thought to be complete by the DN2b stage, which is 
distinguished from the DN2a stage based on decreased levels of Kit expression. While 
DN2a and DN2b cells express CD44 and Kit, these markers are downregulated as cells 
transition to the DN3 stage. DN3 cells have undergone TCRβ gene rearrangement and if 
this is successful (in-frame), they express the pre-TCR complex (TCRβ and the invariant 
preTCRα chain) on their surface85. DN3a cells that receive pre-TCR signals survive, thus 
passing the β-selection checkpoint, and upregulate CD28 to become DN3b cells86. As 
cells undergo T-lineage specification and β-selection, they shut down the expression of a 
suite of “legacy” stem/progenitor cell genes (such as Meis1, Mef2c, Lmo2, Bcl11a, Erg, 
Hoxa9, and others) that promoted extensive proliferation in upstream progenitors; 
failure to do so may antagonize T cell development or contribute to malignant 
transformation87. DN3b cells lose CD25 expression to become DN4 cells, which then 
proceed through a CD4–CD8+TCRβ– immature single positive stage (iSP) and then give 
rise to CD4+CD8+ double positive (DP) cells. DP thymocytes will express mature TCRα/β 
on their surface and undergo positive and negative selection on MHC-peptide complexes 
presented by thymic epithelial cells. DP thymocytes commit to either the CD4 or CD8 
lineage, downregulate the other co-receptor, and exit the thymus. 
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1.5 T cell lineage commitment  
 
Since the identification of ETPs69, much work has characterized the 
developmental potentials possessed by this population. In addition to robust T cell 
developmental potential, ETPs have been shown to possess B cell, DC, NK/ILC potential, 
and a degree of myeloid potential53,64–66,82,83,88–90. Less is known about whether ETPs 
actually adopt alternative (non-T cell) fates in vivo. Nevertheless, these data have 
contributed to an ongoing debate about the models of hematopoiesis described above, 
because at least some thymus settling progenitors (TSPs) are not lymphoid restricted 
and retain myeloid potential. Below, I discuss mechanisms that constrain alternative 
fates in T cell progenitors on the path to T lineage commitment.  
 
 
Inhibition of B cell potential  
 
Progenitors rapidly lose B cell potential upon entry into the thymus, presumably 
in response to intrathymic Notch signals, since Notch is a potent inhibitor of B cell 
development67. Hence, B potential is only detected in a small fraction of the most 
primitive (Flt3+) ETPs found in the adult thymus67. B cell potential is diminished in the 
subsequent Flt3– ETP stage.  As is discussed below, these progenitors that have largely 
extinguished B cell potential retain a degree of myeloid potential. The close 
developmental relationship between T cells and B cells, which both rely on RAG-
mediated antigen receptor rearrangement for their development, perhaps makes it 
puzzling that T cell precursors would lose B cell potential before losing myeloid 
potentials.  On the other hand, there may be significant need to inhibit B cell 
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development within the thymus, since the thymus microenvironment contains cytokines 
supportive of both B and T cells in rich supply. 
 
Notch deficiency results in an abundance of thymic B cells. This may partially 
reflect entry of B cells and/or B cell progenitors into the “empty” thymus, in addition to 
diversion of T cell progenitors to the B cell fate67,68,73,88.  B cell fate inhibition is probably 
mediated by cooperation between multiple Notch effectors such as Hes1, TCF-1, and 
GATA-3 (refs. 91,92). The role of thymic B cells is unclear; however, they localize to the 
thymic medulla and have been suggested to function in negative selection of developing 
thymocytes93. 
 
Inhibition of myeloid potential 
 
In contrast to B cell potential, the ability to access myeloid fates is maintained 
until just before the onset of T lineage commitment at the DN2b stage. Thus, myeloid 
potential is clearly retained longer than B cell potential in the adult thymus.  Protracted 
maintenance of myeloid potential may reflect continued expression stem cell “legacy” 
genes during early intrathymic development, which endows early T lineage progenitors 
with tremendous proliferative capacity. Single cell assays using a stromal cell culture 
system have shown that the majority of individual ETP scan give rise to both T cells and 
myeloid cells, including granulocytes and macrophages64,65.  The question remained: 
even if ETPs can adopt myeloid fates in in vitro assays, do they do so in vivo?  
Furthermore, if ETPs can access myeloid gene expression programs and adopt myeloid 
fates in the thymus, then this suggests the need for a mechanism to attenuate myeloid 
gene expression as cells progress down the T cell lineage. Notch is a strong inhibitor of 
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myeloid development, and likely constrains myeloid potential at very early stages of 
intrathymic T cell development; however, the mechanisms by which this occurs remain 
unclear49,94. One such mechanism, may be the repressor Bcl11b, since its deficiency 
prevents progenitors from shutting down access to myeloid fates, perhaps via repression 
of PU.1 and/or C/EBPα95,96. However, Bcl11b is not expressed in ETPs, and thus cannot explain 
constraint of myeloid gene expression in the earliest intrathymic progenitors of T cells.  
 
This thesis addresses the issue of whether ETPs adopt myeloid fates in 
the thymus (Chapter 2) and investigates the mechanisms used to attenuate 
myeloid gene expression programs during early T cell development 
(Chapter 3). We show that the Notch target and transcriptional repressor Hes1 is 
critical for constraining C/EBPα-dependent myeloid gene expression programs in T cell 
progenitors in the thymus97. In addition, ETPs access some myeloid fates in the thymus 
in vivo. Specifically, thymic granulocytes appear to derive almost exclusively from ETPs 
in vivo83. Accordingly, thymic granulocytes, unlike peripheral conventional granulocytes 
are labeled by a history of RAG-1 expression and rely on similar cytokine/chemokine 
receptor and transcription factors as early T cell progenitors for their development (IL-
7Rα, γc, CCR7/9,  and Hes1)83.  T cell progenitors may also contribute to macrophages 
and cDCs in the thymus; however, there are likely to be other efficient sources for these 
lineages83.  
 
The biological significance of myeloid potential in the ETP population is unclear. 
Myeloid lineage cells in the thymus are important for the phagocytosis of negatively 
selected immature T cells; however, these cells would not necessarily have to derive from 
T cell progenitors in order to perform this function and may instead enter the thymus as 
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myeloid progenitor cells or mature myeloid cells.  Having T cell progenitors support 
development of myeloid lineages within the thymus may be an economical solution that 
allows the presence of non-T cells within the thymus without requiring that thymus-
homing molecules be expressed on committed precursors of these other cell types.  
Another idea is that the myeloid potential of ETPs may be the by-product of a stem cell 
“legacy” transcriptional program, which confers early T-lineage progenitors with 
tremendous proliferative capacity87. 
 Differences in the myeloid potential of ETPs between neonates and young adult 
mice support the idea that thymus settling progenitors (TSPs) vary across ontogeny, such 
that adult TSPs retain a greater degree of myeloid potential98. It is worth noting that that 
fetal and adult intrathymic progenitors differ significantly in their proliferative capacity. 
In adults, ETPs can take 10 days to reach the DN2 stage (compared to little over a day for 
fetal progenitors), and two weeks to generate DP thymocytes (compared to four days for 
fetal mice)99,100. During adult T cell development, the extended time course of T cell 
development corresponds to more extensive proliferation of progenitors. Thus, the 
myeloid potential of adult ETPs may extend the time course of T cell development by 
antagonizing the onset of T cell specification and commitment. Enhanced proliferative 
capacity of adult T cell progenitors can supply increased demand for T cells in the adult 
organism. 
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Inhibition of NK cell/ILC potentials 
 
 ETPs/DN1 thymocytes have also been shown to retain in vitro NK cell potential, 
which is present in a reduced frequency of DN2 thymocytes100,101. In addition to NK cell 
potential, some early thymocyte progenitors have now been shown to retain other innate 
lymphoid cell (ILC) potentials (ILC2 and ILC3). ETP and DN2 thymocytes display ILC2 
potential when cultured with OP9-DLL1 stromal cells in the presence of IL-7 and IL-3360. 
A subset of DN2 fetal thymocytes (α4β7+RORγt-) generate LTi cells after culture with 
OP9 stromal cells; however, culture with Notch ligands (OP9Delta stromal cells) 
abrogates LTi development from these cells102. These α4β7+RORγt- DN2 cells may 
generate LTi-like cells (α4β7+RORγt+) in thymic niches that lack Notch ligands75,102,103.   
 
Notch signals appear to inhibit NK cell generation in vitro101. Downstream of 
Notch, the repressor Bcl11b likely constrains access to NK cell fates, as is discussed in 
greater detail below95,96,104. Bcl11b expression is sharply upregulated in DN2 thymocytes 
by Notch signaling, likely via direct control as well as by the Notch effectors TCF-1 and 
GATA-3, as well as Runx1105. ChIP analysis has shown that Bcl11b is a canonical Notch 
target gene104. Bcl11b continues to be expressed during subsequent stages of intrathymic 
T cell development, even after Notch signaling terminates in DP and SP thymocytes.  
Germline Bcl11b-deficiency results in a block in T cell development at the DN2-DN3 
stage, reduced thymic cellularity and predisposition to lymphomagenesis106. 
Interestingly, Bcl11b heterozygous mice show a similar phenotype105. The defect is not 
exclusively due to increased apoptosis, since generation of DP thymocytes is not restored 
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by p53 deletion107. Bcl11b is thought to act mainly as a repressor during T cell 
development, as there is little evidence for its positive regulation of T cell lineage genes87.  
 
Bcl11b-deficient DN2 thymocytes have been shown to undergo T lineage 
specification indicated by expression of Tcf7, Gata3, CD3g, Ptcra, and Rag1; however, 
Bcl11b-deficient DN2s inappropropriately express genes which are normally 
downregulated by the DN2 stage (Tal1, Bcl11a, Sfpi1, Erg, Flt3) and genes associated 
with innate and “innate-like” lymphocytes (Id2, Il2rb, and Nfil3)96. It remains to be 
determined whether these genes are direct targets of Bcl11b. The mechanism by which 
Bcl11b restricts NK lineage gene expression is unclear; however, one idea is that Bcl11b 
may do so indirectly by promoting E-protein function87. E-proteins are known to inhibit 
NK cell programs; however, the downstream mechanisms are unknown108.  
 
Furthermore, cells resembling NK cells, called “induced-T-to-NK” (ITNK) cells, 
are generated from Bcl11b-deficient DN1, DN2, or DN3 thymocytes in OP9 or OP9-DL1 
cultures instead of T cells 104. Intriguingly, Bcl11b is not only necessary for T cell 
development, but is also required in committed and mature T cells to restrict access to 
NK cell programs. Acute deletion of Bcl11b in mature T cells results in the generation of 
T cells expressing many genes associated with NK cells (NKG2A/C/E, perforin, TRAIL, 
and IFNg, but not Ly49 family receptors) in addition to retaining TCR surface 
expression 104. Roles for Bcl11b have been found for DP thymocyte survival and positive 
selection 109. Thus, Bcl11b plays a critical role in enforcing T cell lineage commitment.  
 
 
 Thymic NK cells are intact in the context of Notch1 deficiency, although ETP 
development in these mice is abrogated110. While this suggests that thymic NK cells 
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derive independently of T cell progenitors, it does not exclude the possibility that T cell 
progenitors unable to progress down the T cell pathway instead adopted NK cell fates. 
Alternatively, thymic NK cells may derive from ETPs in vivo since they require GATA-3 
and IL-7R signaling for their development111. Thus, thymic NK cells have distinct 
developmental requirements from peripheral cNK cells. While the function of thymic NK 
cells is unknown, proposed roles include immunosurveillance of thymocytes, preventing 
transformation, or regulation of thymopoiesis and selection110,112,113. LTi-like cells in the 
thymus may induce AIRE+ mTEC formation114.   
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1.6 Transcription factor networks in hematopoiesis 
 
 
In the hematopoietic system, B cell and erythroid development have been 
extensively studied, and offer a useful point of comparison to understand the 
outstanding questions in the T cell development field. During B cell development, E2A 
initiates a feed-forward regulatory circuit that imposes and maintains B cell identity, by 
upregulating factors such as FOXO1, EBF1, and Pax5.  The B lineage-specific 
transcription factors EBF and Pax5 appear to mediate both lineage specification and 
commitment. In the absence of either EBF or Pax5, the fidelity of B cell lineage identity 
is compromised.  Pax5-deficient progenitors express B-lineage genes, but are unable to 
commit to the B cell fate115,116. Pax5 potently inhibits T cell development by repressing 
Notch1 expression. EBF has been shown to repress other T-lineage regulators, including 
Gata3 and Tcf7, as well as the myeloid regulators Cebpa and Sfpi1, and the E-protein 
antagonist Id2, implicated in ILC development117–119. Hence, EBF deletion in proB cells 
causes upregulation of Id2 and diversion to ILC fates119. Furthermore, EBF and Pax5 
each repress critical T cell/ILC regulators: Notch, GATA-3, and Tcf7118–120. Thus, EBF 
and Pax5 coordinately play a dominant role in B cell lineage commitment by 
antagonizing key regulators of multiple alternative fates. During erythropoiesis, GATA-1 
plays a similar central role in specifying and maintaining the erythroid fate, through 
cooperation with multiple cofactors121–123.  
 
 
 
 
22 
 
In contrast to erythropoiesis or B cell development, a considerably wider “cast of 
characters” (rather than a single or few factors) appears to be necessary to perform the 
positive and negative regulatory functions of T lineage commitment. A single “master 
regulator” which dominates the execution of positive and negative regulatory events in T 
cell development has eluded identification.  T cell development transcription factor 
networks are not dominated by feed-forward loops, as is the case for B cell development.  
Instead, there is a complex division of labor, and considerable redundancy between 
multiple regulatory factors.  T cell commitment relies not only on several key lineage-
specific transcription factors, among these: TCF-1, GATA-3, Bcl11b, but also a host of 
other factors expressed across hematopoietic lineages including E2A, Runx1/CBFβ, Gfi1, 
Myb, and PU.1.  The mechanisms resulting in T lineage specification, particularly the 
dramatic upregulation of T cell lineage genes between the DN2 and DN3 stages of 
thymocyte development, remain unclear. One possibility is that T lineage specification is 
mediated by combinatorial action of multiple cooperating positive regulators. Another 
fascinating idea is that T lineage specification is indirectly mediated by negative 
regulation of stem/progenitor genes expressed by early thymocyte progenitors. This is 
because some stem/progenitor genes expressed during early stages of intrathymic T cell 
development, such as SCL and Lyl1 have been shown to inhibit the activation of T-
lineage positive regulators by E-proteins87.  
 
In this thesis, we focus on understanding the negative regulatory mechanisms 
that constrain gene expression associated with alternative fates, particularly the myeloid 
fate, during early T cell development. The asynchronous loss of non-T cell potentials 
during early T cell development suggests that multiple factors are needed to shut down 
different alternative fates in T cell progenitors. Notch signaling has been implicated in 
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alternative fate inhibition; however, the mechanisms downstream of Notch responsible 
for T lineage commitment have remained unclear. We examined one effector of Notch 
signaling, Hes1 as a possible mechanism that constrains access to myeloid gene 
expression programs in early T lineage progenitors.  
 
The Notch signaling pathway is highly conserved in all metazoans and plays a key 
role in the development of many mammalian organ systems. The upregulation of Hes 
factors by Notch1, in cooperation with the E-protein E47 is evolutionarily conserved in 
Drosophila sensory organ development and in the notochord of ascidians124–126. Hes1 is a 
mammalian homologue of Drosophila hairy and Enhancer of split127. Hes1 is a basic 
helix-loop-helix (bHLH) transcriptional repressor and an evolutionarily conserved target 
of Notch signaling128. In this work, we show that Hes1 is critical for constraining myeloid 
transcriptional programs in T cell progenitors. TCF-1 and GATA-3 likely cooperate to 
inhibit B cell development extremely rapidly following thymic entry. The repressor 
Bcl11b has been shown to be critical for silencing NK and myeloid programs just prior to 
commitment. Therefore, multiple distinct mechanisms downstream of Notch cooperate 
to mediate suppression of alternative fates. Consistent with this idea, analysis of 
sequential T cell progenitor populations by ChIP and deep sequencing has revealed that 
diverse histone modifications mark different genes encoding hematopoietic regulatory 
molecules across development129. It is interesting to consider why and how a system 
using distinct mechanisms to constrain different alternative lineage cell fates evolved in 
the thymus, as opposed to a single mechanism that represses all but the T cell fate. The 
existence of distinct modules downstream of Notch signaling suggests the possibility that 
these modules are also used elsewhere in the hematopoietic system. Indeed, Hes1 is 
known to repress C/EBPα in multiple cell lineages with diverse developmental 
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outcomes. Indeed, during mast cell development, Notch2 signaling upregulates the 
expression of Gata3 (which encodes the transcription factor and T cell regulator GATA-
3) and Hes1, which is thought to repress the gene encoding C/EBPα (Cebpa) and prevent 
diversion of mast cell progenitor cells to other myeloid fates130.  Hes1 also appears to 
antagonize C/EBPα, a critical regulator of the development of adipogenesis, in 
preadipocyte progenitors131.  
 
The findings presented in this thesis identify the Notch target and transcriptional 
repressor Hes1 as an important mechanism that constrains myeloid gene expression 
programs in T cell progenitors. Hes1 deficiency in hematopoietic progenitors severely 
compromises T cell development; however, this defect can be completely rescued by 
deletion of the myeloid regulator C/EBPα. Thus, our findings indicate that ETPs are 
bona fide myelo-lymphoid progenitors and establishes the critical importance of 
constraining myeloid developmental programs early in T cell development.  
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1.7 Figures 
  
 
Figure 1-1 Overview of hematopoiesis 
 
Hematopoietic stem cells (HSCs) are pluripotent, self-renewing cells which give rise to 
downstream progenitors such as multipotent progenitors (MPP) and lymphoid primed 
multipotent progenitors (LMPP), which have upregulated expression of the cytokine receptor 
and have lost self-renewal capacity.  LMPP are the 25% of MPP with the highest Flt3 
expression.  
 
The classical model of hematopoiesis posits that downstream of the LMPP, there is an 
obligate bifurcation between myeloid and lymphoid lineages that results in the generation of 
common myeloid progenitors (CMP) and common lymphoid progenitors (CLP). In the 
classical model, CMP are the precursors of megakaryocytes, erythrocytes and all myeloid cell 
types.  
 
The revised model of hematopoiesis posits that LMPPs, which have lost megakaryocyte and 
erythroid potential, give rise to granulocyte/monocyte progenitors (GMP) and common 
lymphoid progenitors. In the revised model, both CLP and LMPP contribute to T cell 
generation in the thymus (blue arrow). 
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Figure 1-2 Overview of T lymphopoiesis 
 
T cells complete their maturation in the thymus from circulating bone marrow-derived 
progenitors. While HSC, MPP, LMPP, and CLPs all have T cell potential, only LMPPs are found 
in the blood. A subset of LMPPs and CLPs express chemokine receptors important for thymic 
homing, CCR7 and CCR9, and can thus settle the thymus following IV transfer.  It is unclear to 
what extent LMPP and CLP each contribute to thymic T cell development.   
 
Thymus settling progenitors have not been identified within the thymus (as indicated by the 
question mark above), but these cells proliferate and differentiate upon receiving Notch 
signaling to form the ETP population. ETPs are double-negative (DN) for CD4 and CD8 co-
receptors. Notch launches the T cell program in DN thymocytes. 
 
T cell fate specification is evident at the DN2 stage, and cells first become committed to the T 
cell fate at the DN2b/DN3 stage. Notch signaling terminates after the DN3 stage, as 
thymocytes become double positive (DP) for the CD4 and CD8 coreceptors. Following positive 
and negative selection of the T cell receptor, DPs become either CD4 or CD8 single positive 
cells (“T”) and exit the thymus.  
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Figure 1-3 Notch signaling overview  
 
Notch receptors span the cell membrane of the signal receiving cells. When the 
extracellular portion of the Notch receptor is bound by Notch ligand on the signal 
sending cell, this induces proteolytic cleavage of the receptor and releases the 
intracellular domain of Notch (ICN), which translocates to the nucleus to alter gene 
expression. 
In the nucleus, ICN forms a transcriptional activation comples with the RBP-Jk/CSL 
protein, mastermind-like (MAML), and co-activators, such as p300 in order to initiate 
transcription of Notch target genes, such as Hes1.  
 
Source: Will Bailis and Warren Pear, University of Pennsylvania 
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Figure 1-4 Gating of thymus and BM progenitors  
 
A) Adult mouse thymus stained for CD4 and CD8 co-receptors to delineate CD4/CD8 
double negative (DN) and CD4/CD8 double positive (DP) thymocyte populations. 
B) DN thymocyte populations are defined as ETPs (Lin–Kit+CD25–), DN2 cells (Lin–
Kit+CD25+), and DN3 cells (Lin–Kit–CD25+)  
C) The BM LSK population is enriched for HSC activity and was gated to include Lin–
Sca-1+Kit+ cells. BM lymphoid-primed multipotential progenitor cells (LMPP) reside 
within this population and were sorted as Lin–Sca-1+Kit+Flt3+ cells (not shown here). 
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CHAPTER 2:  ETP GENERATE T CELL AND MYELOID PROGENY IN VIVO 
 
2.1 Abstract 
 
 The mouse thymus is primarily composed of developing T cells, but also contains 
alternative (non-T cell) lineages such as dendritic cells (DC), macrophages, and 
granulocytes that are necessary for T cell repertoire selection and apoptotic thymocyte 
clearance.  Early thymic progenitors (ETPs) are not committed to the T cell lineage as 
demonstrated by both in vitro and in vivo assays. Whether ETPs realize alternative 
lineage potentials in vivo is not well understood and indeed controversial. Here, we 
examine whether ETPs are the major precursors of any alternative lineage cell types in 
the thymus. We analyzed development of these populations using a RAG-1 fate mapping 
approach and under experimental circumstances in which ETPs are nearly absent, either 
due to abrogated thymic settling, or due to genetic ablation of factors required for early 
thymic development (IL-7Rα and common γ-chain). Results obtained using multiple in 
vivo approaches indicate that the majority of thymic granulocytes derive from ETP. 
These data indicate that myelo-lymphoid progenitors settle the thymus, and thus clarify 
the pathways by which stem cells give rise to downstream blood cell lineages.  
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2.2 Introduction 
 
Since the identification of early T-lineage precursors (ETPs)69, much work has 
characterized the developmental potentials possessed by this population64–
67,82,83,89,90,132,133.  In addition to robust T cell developmental potential, ETPs have been 
shown to possess B cell, DC, NK/ILC potential, and a degree of myeloid potential. As 
ETPs progress along the T cell developmental pathway, they gradually lose alternative 
lineage potentials. ETPs generate CD4/CD8-double negative 2 (DN2) progenitors, which 
have undergone T cell specification, and then DN3 cells that are committed to the T cell 
lineage.  
 
Single cell assays using a stromal cell culture system have shown that the 
majority of individual ETPs can give rise to both T cells and myeloid cells, including 
granulocytes and macrophages64–66. However, less is known about the extent to which 
ETPs realize this myeloid potential and other non-T cell lineage potentials in vivo. We 
previously reported that about half of ETPs and a similar fraction of thymic granulocytes 
were labeled in H2-VEX V(D)J recombination reporter mice65.  These data are consistent 
with the notion that thymic granulocytes share a common origin with T cells.  Since then, 
another study examining thymic myeloid cells using an IL-7R/Cre lineage tracing 
approach yielded discordant results53. Thus, further examination was needed to 
determine whether ETPs can produce granulocytes in vivo, and whether ETPs are the 
major precursors of thymic granulocytes. Understanding whether ETPs generate both 
myeloid and T cell progeny in vivo will contribute to a more complete model of 
hematopoietic development.  
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We examined thymic granulocyte development in experimental contexts where 
ETPs are nearly absent. We reasoned that any alternative lineage cells in the thymus that 
are unperturbed in the absence of ETP in mixed BM chimeras must not predominantly 
derive from ETPs. Previous studies have used a similar approach to investigate whether 
alternative lineage cells in the thymus originate from T cell progenitors; yet, these 
studies did not examine thymic granulocytes72,88.  Studies that exclusively rely on models 
that block intrathymic ETP development (for example, ablation of Notch signaling) may 
fail to detect that alternative lineage cells derive from T cell progenitors. This is because 
progenitors continue to settle the thymus and may still generate alternative lineage cells 
even when ETP development is abrogated. To address this concern, we chose to study 
development of alternative lineage cells in the thymus by eliminating T cell progenitors 
prior to thymic entry. Specifically, we have examined mixed chimeras using CCR7/CCR9 
double-deficient donor BM, in which T cell progenitors display defective thymic settling 
and hence generate almost no ETPs134,135. In addition, we have examined thymic 
granulocyte development when factors necessary for early thymic development, 
including IL-7Rα and the common γ-chain (CD132) are absent. Thus, we have 
undertaken multiple complementary approaches to investigate the origin of thymic 
granulocytes and other alternative lineage cells in the thymus in order to account for 
possible confounding factors associated with a single approach. 
 
Across several different in vivo experimental systems, we have consistently 
implicated ETPs as the major precursors of thymic granulocytes. In all models we have 
analyzed, we found that thymic granulocytes have distinct developmental history and 
developmental requirements from their extrathymic counterparts. Thymic granulocytes, 
like ETPs, but unlike other granulocytes, show a history of RAG-1 expression and depend 
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on CCR7/CCR9, IL-7Rα, and the common γ-chain (CD132) for their development. These 
data are compatible with the notion that ETPs give rise to the bulk of thymic 
granulocytes in vivo. ETPs may also contribute to other alternative lineage cells in the 
thymus for which they have demonstrated potential, such as macrophages, DCs, and B 
cells; however, these lineages derive predominantly from progenitors other than ETPs. 
Hence, although ETPs possess many alternative lineage potentials, they are the major 
precursors for only a select subset of these lineages in the thymus.  
 
2.3 Results 
2.3.1 Thymic granulocytes have a developmental history of RAG-1 
expression 
 
We first characterized the Mac1+Gr-1+ thymic granulocyte population (Figure 2-1 
A). Thymic Mac1+Gr-1+ cells had polynuclear morphology characteristic of granulocytes, 
and distinct from lymphocytes (Figure 2-1 B). To verify that Mac1+Gr-1+ cells in the 
thymus were myeloid and not T-lineage cells, we made competitive chimeras by 
transplanting CD45.2+ Cebpafl/flVav1-Cre FL and CD45.1+ competitor BM into lethally 
irradiated CD45.1+ recipients. We verified that Mac1+Gr-1+ cells in the thymus are 
dependent on the myeloid transcription factor C/EBPα, like granulocyte populations 
outside the thymus (Figure 2-1 C). Thus, the Mac1+Gr-1+ population in the thymus is not 
contaminated with T-lineage cells, since T cell development is unaffected by C/EBPα 
deficiency136. 
 
Lymphocyte progenitors form functional antigen receptors via rearrangement of 
antigen receptor loci during the process of V(D)J recombination.  This process requires 
Recombinase Activating Gene (RAG) enzymes RAG-1 and RAG-2, the expression of 
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which is restricted to lymphocyte precursors. Some thymic granulocytes were previously 
shown to be labeled in H2-VEX V(D)J recombination reporter mice65. Based on this 
finding, we wished to directly test whether ETPs can give rise to granulocytes labeled by 
a recombination reporter following direct intrathymic injection. For these experiments, 
we made use of RAG-1/Cre mice in which RAG-1 promoter elements control Cre 
recombinase expression137,138. We bred these mice to mice with a floxed stop cassette 
upstream of the gene for YFP, which has been inserted into the ubiquitously expressed 
Rosa26 locus.  Thus, in RAG-1/Cre x Rosa26-YFP mice, RAG-1-expressing cells and their 
progeny are permanently marked by YFP expression. The RAG-1/Cre mouse was 
superior to the H2-VEX V(D)J reporter for this experiment, which entailed analysis of 
rare thymic granulocyte populations, because the YFP reporter provides greater 
fluorescence intensity and sensitivity. 
 
Similar to the labeling of ETPs in H2-VEX V(D)J recombination reporter mice, 
we found that over half of ETPs were labeled in RAG-1/Cre x Rosa26-YFP mice (Figure 
2-2 B,C).  We also examined whether granulocytes and other alternative lineage cells in 
the thymus were labeled in these mice. Since RAG expression is restricted to lymphocyte 
precursors, labeling of a non-lymphoid population would suggest that this population 
originated from a progenitor that had expressed RAG-1 at some point during its 
development. We examined granulocyte and conventional DC (cDC) populations in the 
adult mouse thymus and spleen (Figure 2-2 A) for a history of RAG-1 expression in RAG-
1/Cre x Rosa26-YFP mice. We found that more than half of thymic granulocytes were 
labeled; however, only about 2% of splenic granulocytes were labeled (Figure 2-2 B,C). 
Thymic CD11chi cDCs including CD8α+ cDCs and Mac1+ cDCs, were less than 5% labeled, 
which is similar to the level of labeling in splenic cDC populations (Figure 2-2 B,C). These 
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results are consistent with the idea that RAG-1-expressing ETPs give rise to thymic 
granulocytes, but not thymic cDCs.  Moreover, thymic granulocytes have a distinct 
developmental history compared to peripheral granulocytes.  
 
We also examined neonatal RAG-1/Cre x Rosa26-YFP mice, and found that 
despite the fact that over half of ETPs were labeled with a history of RAG-1 expression, 
thymic granulocytes were largely unlabeled at 0-12 hours after birth (Figure 2-3).  
Interestingly, the frequency of RAG-1/Cre-YFP+ thymic granulocytes increased by 5 days, 
perhaps trending towards the similar degree of RAG-1/Cre labeling between ETPs and 
thymic granulocytes that we observed in adult mice (Figure 2-2). The frequency of RAG-1 
labeled granulocytes in neonatal blood was generally low (as it is in adult blood – data 
not shown), though we were surprised to see as many as 20% of blood granulocytes 
labeled by RAG-1/Cre at 5 days. As others have reported66, the frequency of ETPs in the 
thymus is higher in neonatal mice, compared to 20 day old mice (Figure 2-3).  
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2.3.2 ETPs can generate granulocytes in vivo 
 
Labeling of ETPs as well as thymic granulocytes in RAG-1/Cre x Rosa26-YFP 
mice suggested that thymic granulocytes may derive from ETPs. In order to directly test 
whether ETP can give rise to granulocytes with a history of RAG-1 expression, we sorted 
thymocyte progenitor populations from RAG-1/Cre x Rosa26-YFP mice and injected 
them directly into the thymus of sublethally irradiated congenic CD45.1+ recipients 
(Figure 2-4 A). We injected either pooled CD45.2+ ETPs and DN2 progenitors or DN3 
progenitors. We then examined donor contribution to thymic granulocyte populations 6 
days after injection. We found that pooled ETPs and DN2 thymocytes gave rise to 
CD45.2+ thymic granulocytes that were YFP+, indicating a history of RAG-1 expression 
(Figure 2-4 B).  As expected, control DN3 thymocytes, which are T-lineage committed, did 
not generate thymic granulocytes.  These data show that ETPs can generate granulocytes 
in vivo within the thymus, and that these granulocytes show a history of RAG-1 
expression.  
 
We next wished to establish the kinetics with which ETP-derived thymic 
granulocytes can be detected following intrathymic injection. A previous study found no 
ETP-derived thymic granulocytes 11 or 16 days post-injection53; however, we considered 
that an earlier time point may be appropriate, given the short lifespan of granulocytes139. 
Thus, we intrathymically injected CD45.2+ ETPs into sublethally irradiated CD45.1+ 
congenic recipient mice and examined the donor contribution to thymic granulocytes 6 
or 11 days post-injection.  Consistent with the results in Figure 2-4, we found that ETPs 
gave rise to Mac1+Gr-1+ thymic granulocytes at 6 days post-injection, but these can no 
longer be detected 11 days post-injection (Figure 2-5 A). Again, DN3 thymocytes, which 
are T-lineage committed, did not generate thymic granulocytes. As expected, both ETP 
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and DN3 cells produced CD25+ T-lineage progeny following intrathymic injection at both 
time points examined (Figure 2-5 B). Thus, ETPs have the capacity to generate 
granulocytes in vivo at early time points. 
 
We next examined different progenitor population in adult BM for their ability to 
give rise to myeloid granulocytes following intrathymic injection. We found that Kithi 
progenitors (a population which includes LMPPs) expressing the thymic homing 
molecule CCR9 were able to generate myeloid granulocytes, as were ETPs and BM 
myeloid progenitors (Figure 2-6). The kinetics of granulocyte production from ETPs, 
KithiCCR9+ BM progenitors, and BM myeloid progenitors was different, with ETPs only 
giving rise to granulocytes at 6 days post-injection. Myeloid progeny of BM progenitors 
were detectable at 6 and 11 days post-injection, consistent with BM progenitors being 
more developmentally primitive than intrathymic progenitors. In contrast kitlo 
progenitors from the BM (analogous to CLPs), sorted to express CCR9 were not able to 
generate granulocytes following intrathymic injection, distinguishing them from ETP.  
 
2.3.3 Thymic granulocyte development is impaired in the absence of thymic 
settling by T cell progenitors 
 
Our results with RAG-1/Cre x Rosa26-YFP mice suggested that at least a fraction 
of thymic granulocytes derived from ETPs. We therefore asked whether development of 
thymic granulocyte populations was dependent upon the ability of T cell progenitors to 
settle the thymus in mixed BM chimeras. The strategy used to generate mixed BM 
chimeras is shown in Figure 2-7. Thymic settling by T cell progenitors is impaired in 
mice that are doubly-deficient for chemokine receptors CCR7 and CCR9134,135. Indeed, 
ETPs are almost completely absent from CCR7/CCR9 double-deficient BM in mixed 
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marrow chimeras (Figure 2-8 A), despite normal engraftment of BM Lin–Sca1+Kit+ (LSK) 
progenitors (Figure 2-8 B). We therefore examined the ability of CCR7/CCR9 double-
deficient BM to reconstitute alternative lineage cells in the thymus of mixed marrow 
chimeras.  We reasoned that if a particular thymic lineage predominantly originates from 
ETPs, then the donor chimerism of this population would necessarily be reduced in the 
absence of CCR7 and CCR9. Alternatively, if a particular thymic lineage develops 
independently of both CCR7 and CCR9, then it is unlikely to develop from ETPs. Indeed, 
we found that the development of thymic granulocytes was diminished from CCR7/CCR9 
double-deficient donor BM (Figure 2-8 A), whereas splenic granulocyte chimerism was 
unaffected (Figure 2-8 B). These results are consistent with the idea that most thymic 
granulocytes develop from ETPs.  
 
We additionally examined the development of conventional DC (cDC) subsets in 
the thymus of CCR7/CCR9 double-deficient mixed marrow chimeras. Thymic Mac1+ 
cDCs were unperturbed in the absence of CCR7 and CCR9; however, we consistently saw 
a 50% decrease in thymic CD8α+ cDC donor chimerism (also referred to as “Mac1– 
cDCs”) from CCR7/CCR9-deficient BM (Figure 2-8 A).  Both CD8α+ and Mac1+ cDC 
subsets in the spleen were unaffected by CCR7/CCR9-deficiency (Figure 2-8 B).  
 
We next examined whether CCR7/CCR9 deficiency affected the development of 
macrophages and B cells within the thymus (Figure 2-9). We saw a modest reduction in 
the development of thymic macrophages from CCR7/CCR9 double-deficient progenitors 
(Figure 2-10); however, this difference did not reach statistical significance. There was a 
decrease in contribution of CCR7/CCR9-deficient BM to CD19hiB220hi thymic B cells 
(Figure 2-10). As expected, CCR7/CCR9-deficiency did not alter macrophage or B cell 
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development in the spleen (Figure 2-10). Our study cannot exclude the possibility that 
the absence of CCR7/CCR9 leads to reduced settling of the thymus by CD8α+ cDCs, 
macrophages, B cells, or their precursors. In summary, these results indicate that at least 
50% of thymic CD8α+ cDCs, all thymic Mac1+ cDCs, and the major fraction of 
macrophages and B cells in the thymus develop independently of ETPs.  
2.3.4 Thymic ETP and granulocyte development depend on IL-7Rα  and the 
common γ-chain  
 
We next wished to determine whether cytokine signals critical for T cell 
development are also required for the development of granulocytes in the thymus. IL-7 
signaling is critical for the development of T cells and B cells, but is dispensable for 
granulocyte production140,141.  IL-7 signals through the IL-7 receptor (IL-7R), which is 
composed of the IL-7Rα (CD127) and the common γ-chain (CD132) (ref. 142). We 
examined whether development of granulocytes in the thymus is dependent on IL-7R 
signaling; if so, this would support a model in which thymic granulocytes share a 
common origin with T cells. We constructed mixed chimeras using IL-7Rα-deficient BM 
and examined the development of ETP and thymic granulocytes after 8 weeks. The IL-
7Rα–/–donor chimerism of both ETP and thymic granulocytes was significantly reduced 
compared to BM LSK chimerism (Figure 2-11 A), indicating a role for IL-7Rα signaling in 
the development of both populations. Granulocytes in the spleen were unaffected by IL-
7Rα deficiency (Figure 2-11 B).   
 
To validate these results we also examined ETP and thymic granulocyte 
chimerism in mixed BM chimeras using common γ-chain (CD132)-deficient bone 
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marrow. This was necessary because the IL-7Rα not only pairs with common γ-chain, 
but also with the thymic stromal lymphopoietin receptor (TSLPR). Similar to IL-7Rα 
deficiency, we also observed defective ETP and thymic granulocyte development from 
common γ-chain (CD132) deficient BM (Figure 2-12 A,B). Splenic granulocytes developed 
normally in the absence of the common γ-chain, consistent with the dispensability of 
common γ-chain cytokines (IL-2, IL-4, IL-7, IL-9, IL-15) in peripheral myeloid 
development (Figure 2-12 C). Thus, the CD132-dependence of these populations, suggests 
that their IL-7Rα dependence is not exclusively due to a deficiency in TSLPR signaling. 
These data are consistent with the notion that most thymic granulocytes derive from T 
cell precursors (Figure 2-1).  
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2.4 Discussion 
 
The earliest progenitors of T cells in the mouse thymus retain a variety of 
alternative or non-T-lineage potentials; yet it has remained controversial whether these 
potentials are realized within the thymus in vivo. Using multiple in vivo models, we 
found that thymic granulocytes have a distinct origin from peripheral granulocytes. 
Furthermore, our study implicates ETP as the major precursors of thymic granulocytes.  
Thymic granulocytes differ from their peripheral counterparts in several ways that 
suggest a close developmental relationship with T cell progenitors: 1) they are labeled by 
a history of RAG-1 expression; 2) they are diminished in the absence of chemokine 
receptors necessary for thymic settling by T cell progenitors; 3) they rely on IL-7Rα and 
the common γ-chain (CD132) for their development.  These properties together provide 
strong evidence that thymic granulocytes and T cells derive from the same precursors.  
 
Recent work using an IL-7R/Cre lineage tracing approach found that less than 
20% of Mac1+Gr-1+ thymic granulocytes were labeled with a developmental history of IL-
7R expression, and concluded that T cells and myeloid cells in the thymus have separate 
origins53. However, we find that thymic granulocytes depend on IL-7Rα for their 
development. The simplest explanation for this apparent discrepancy is that lineage-
tracing approaches require a threshold level of Cre recombinase expression, whereas 
cytokine receptors can be active at levels below this threshold143. Thus, cellular 
responsiveness to cytokine is a more sensitive readout than reporter labeling144. Hence, 
although thymic granulocyte precursors do not reach the threshold level of Cre 
expression needed to confer labeling in IL-7R/Cre reporter mice, they are clearly 
revealed to require IL-7Rα in our studies.  Our results argue against the conclusions 
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reached using the IL-7R/Cre lineage tracing approach, and reveal that most thymic 
granulocytes share a common origin with T cells.  
 
This study indicates that cells of the same lineage can arise from distinct 
progenitors in different sites. Similarly, DCs can derive from either myeloid or lymphoid 
progenitors145. We verified that thymic Mac1+Gr-1+ cells have polynuclear morphology 
and depend on the transcription factor C/EBPα for their development, thus confirming 
their identity as myeloid cells. Although the function of thymic granulocytes is not 
precisely known, it is possible that these cells act as scavengers of apoptotic thymocytes. 
Because the vast majority of developing thymocytes will fail positive or negative 
selection, scavenger cells, such as macrophages, play an important role in 
thymopoiesis146,147. A recent study showed that mice deficient for neutrophil migration 
were impaired in their ability to clear apoptotic cells following irradiation148. Thus, it is 
possible that granulocytes function as scavengers of apoptotic thymocytes in the steady 
state.  
 
Granulocytes are unique among non-T-lineage cells in the thymus, in that their 
major precursors appear to be ETPs. Indeed, our data suggest that there are not other 
efficient sources of thymic granulocytes apart from ETPs. The frequencies of donor-
derived thymic macrophages and B cells from CCR7/CCR9 double-deficient progenitors 
were reduced compared to wild-type controls (25% and 37%, respectively), and for B 
cells this achieved statistical significance. Our study cannot exclude the possibility that 
the absence of CCR7 and/or CCR9 leads to reduced settling of the thymus by 
macrophages, B cells, or their precursors. However, our results are in line with other 
work that examined the development of thymic macrophages and B cells and concluded 
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that despite the demonstrated macrophage and B cell potential of ETPs63–66,82,90,132,133, the 
major fraction of these thymic lineages develop independently of ETPs64,88. Hence, ETPs 
may contribute to lineages in the thymus besides granulocytes, but there are likely to be 
more efficient or abundant precursors for these cells than ETPs. It is important to note 
that our conclusions apply only to adult mice. The frequency of ETPs with B-lineage 
potential is increased in neonatal mice66,149, and ETPs may be a more significant source 
of thymic B cells in early life.  Furthermore, our preliminary studies suggest that thymic 
granulocytes may not predominantly derive from ETPs in neonatal mice. 
 
ETPs have been shown to have DC potential in vitro and in vivo upon 
intrathymic injection89,150.  Specifically, CD8α+ thymic cDCs have been proposed to 
originate from ETPs151,152. We found that thymic cDC subsets are unlabeled in RAG-1/Cre 
reporter mice, consistent with previous reports that this population lacks T cell receptor 
rearrangements88. Although thymic cDC development can be uncoupled from T cell 
development in the context of Notch1 deficiency72,88, these studies cannot exclude the 
possibility that thymic cDCs develop from thymus settling progenitors upstream of the 
ETPs.  In the absence of Notch, progenitors continue to arrive at the thymus and fail to 
become ETPs, but may develop into other lineages. Thus, we asked whether thymic cDC 
development would be perturbed by deficiency for CCR7 and CCR9, which results in near 
complete ablation of ETPs in competitive chimeras. We found that about half of CD8α+ 
thymic cDCs derive completely independently of ETPs in CCR7/CCR9-deficient mixed 
marrow chimeras. We cannot exclude the possibility that the absence of CCR7 and/or 
CCR9 leads to reduced settling of the thymus by DC or DC progenitors. A recent study153 
proposed that thymic CD8α+ cDCs derive from DN1c thymocytes, which are not 
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considered canonical T cell progenitors100. These data indicate that most or all thymic 
cDCs, including the CD8α+ subset, derive independently of ETPs.   
 
In summary, this study establishes that T cells and granulocytes in the adult 
mouse thymus derive from a common progenitor. ETPs may generate other alternative 
lineage cells in the thymus; however, they are not the major precursors of these cells. 
These data together with other recent work66 support the notion that some thymus 
settling progenitors are myelo-lymphoid progenitors. Further, the myeloid potential of 
uncommitted T cell progenitors is realized in vivo in the adult mouse thymus. Future 
studies are needed to clarify the mechanisms that control the lineage fate decisions of 
ETPs and their descendants. 
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2.5 Figures 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Thymus Mac1+Gr-1+ cells are confirmed to be C/EBPα-dependent 
myeloid cells  
 
A) Gating of Mac1+Gr-1+ granulocytes in the adult mouse thymus and spleen. 
 
B) Sorted Mac1+Gr-1+ cells in the thymus and CD4/CD8 double-negative (DN) T-
lymphocytes were cytospun and examined by Wright-Giemsa stain at 100X. Scale bars 
represent 10 microns.  
 
C) The development of total CD4+ thymocytes, thymic granulocytes, and splenic 
populations was examined in mixed chimeras of Cebpafl/flVav1-Cre FL or Cebpafl/fl 
control FL and congenic CD45.1+ BM. Two mice were examined per group 10 weeks after 
reconstitution of lethally irradiated CD45.1+ hosts. Two mice were examined per group 
8-10 weeks post-reconstitution. 
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Figure 2-2 Adult thymic granulocytes have a history of RAG-1 expression,  
like ETPs 
 
A) Gating strategy for granulocytes and cDC subsets in thymus and spleen. Note that CD8α and 
Mac1 are expressed on distinct populations of cDCs, such that CD8α+ cDCs may also be gated as 
Mac1- cDCs. 
 
B) Thymus and spleen granulocytes and cDC subsets were examined in RAG-1/Cre x Rosa26YFP 
mice for the presence of YFP labeling. Shaded histograms represent the same population in YFP– 
control mice. 
 
C) The mean percentage of YFP+ cells in each population was quantified. Thymus populations are 
in black bars. Splenic populations are in gray bars. There is no corresponding splenic population 
for ETPs. Three mice per group were examined. Error bars represent standard error of the mean 
(SEM). **P<0.01 for the percentage of YFP+ cells of the indicated population in the thymus 
compared to the spleen. 
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Figure 2-3 Neonatal thymic granulocytes mostly lack a history of  RAG-1 
expression, in contrast to ETPs 
 
RAG-1/Cre-Rosa26YFP littermates were examined shortly after birth (0-12 hours or 5 days) to 
determine the degree of RAG-1/Cre-YFP labeling in ETPs, thymus granulocytes, and blood 
granulocytes. A 20 day old YFP– littermate was also examined as a control. Three mice were 
examined at 0-12 h, and one mouse was examined at 5 d. 
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Figure 2-4 ETPs generate thymic granulocytes with a history of RAG-1 expression 
 
A) Schematic of intrathymic injection procedure 
 
B) ETPs plus DN2 thymocytes or DN3 thymocytes were sorted from CD45.2+ RAG-1/Cre-
Rosa26YFP mice and intrathymically injected into congenic CD45.1+ sublethally irradiated 
recipients (7,000 ETPs+DN2/recipient and 70,000 DN3/recipient). Donor contribution to 
YFP+ thymic Mac1+Gr-1+ cells was examined 6 days post-injection. 
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Figure 2-5 Myeloid potential of ETPs is short-lived 
 
A) ETPs (10,000/recipient) and DN3 thymocytes (50,000/recipient) were sorted from 
CD45.2+ donor mice and intrathymically injected into sublethally irradiated CD45.1+ 
recipients.  Mice were sacrificed 6 or 11 days post-injection and examined for donor 
contribution to Mac1+Gr-1+ thymic granulocytes. Four mice were examined per group.  
 
B) Injection controls: Each panel is from the same mouse as the corresponding panel of 
part A. Donor contribution to CD25+ thymocytes were examined.  
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Figure 2-6 Some BM progenitors will generate myeloid cells in thymus 
 
The indicated thymus or BM progenitors were sorted from CD45.2+ donor mice and injected 
intrathymically into CD45.1+ sublethally irradiated hosts. Donor contribution to thymic 
granulocytes was examined at 6 or 11 days post-injection by flow cytometry. CCR9+kithi LP 
were sorted as LSKithiFlt3+CCR9+ BM. CCR9+ kitlo LP were sorted as LSKitloFlt3+CCR9+ BM. 
Myeloid progenitors were sorted as Lin–Kit+Sca1– cells. Six mice per group were examined. 
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Figure 2-7 Schematic of bone marrow chimera generation 
 
CD45.1+ recipient mice are lethally irradiated and injected intravenously with a 
mixture of CD45.1+ and CD45.2+ cells. After 8-10 weeks, CD45.2+ donor 
contribution to populations of interest is examined by flow cytometry.  
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Figure 2-8 Abrogation of thymic settling diminishes thymic granulocytes 
 
A) Reconstitution of thymic ETPs, granulocytes, and cDCs in the absence of both CCR7 and 
CCR9 was examined in competitive chimeras at 8-10 weeks.  
B) Reconstitution of BM LSK, and splenic granulocytes and cDCs in the absence of both 
CCR7 and CCR9 was examined in competitive chimeras at 8-10 weeks. 
C) Shown is the mean CD45.2+ donor contribution of CCR7/CCR9+/+ (black bars) or 
CCR7/CCR9–/– (gray bars) BM to thymic and extrathymic populations. Eight animals per 
group were examined, over three independent experiments. Error bars represent SEM. 
***P<0.001 for the CD45.2+ donor chimerism of the indicated population compared with 
BM LSK CD45.2+ donor chimerism.  
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Figure 2-9 Gating strategy: granulocytes, macrophages, and B cells in the 
thymus, spleen, or BM 
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Figure 2-10 Thymic macrophages and B cells develop independently of 
thymus settling by T cell progenitors 
 
A) The development of CD45.2+ thymic macrophages and B cells in the absence of both 
CCR7 and CCR9 was examined in competitive bone marrow (BM) chimeras, 8-10 weeks 
after reconstitution of lethally irradiated CD45.1+ hosts.   
 
B) Shown is the mean CD45.2+ donor contribution by CCR7/CCR9+/+ (black bars) or 
CCR7/CCR9–/– (gray bars) donor BM to thymic or splenic macrophage and B cell 
populations. Eight mice per group were examined, over three independent experiments. 
Error bars represent SEM. ***p<0.001 for the CD45.2+ donor chimerism of the indicated 
population compared with BM LSK CD45.2+ donor chimerism. 
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Figure 2-11 Thymic granulocytes are IL-7Rα-dependent 
 
A) The development of CD45.2+ ETPs and thymic granulocytes in the absence of IL-7Rα 
was examined in competitive BM chimeras, 8 weeks post-reconstitution.  
 
B) The development of CD45.2+ BM LSK and splenic granulocytes in the absence of 
IL-7Rα was examined in the same mice.  
 
C) Shown is the mean percent CD45.2+ donor contribution to BM LSK, splenic 
granulocytes, ETPs, or thymic granulocytes by IL-7Rα+/+ (black bars) or IL-7Rα–/– (gray 
bars) BM. Three mice per group were examined. Error bars represent SEM. ***p<0.001 
for the CD45.2+ donor chimerism of the indicated population compared with BM LSK 
CD45.2+ donor chimerism. 
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Figure 2-12 Thymic granulocytes are CD132 (γc)-dependent  
 
A) The development of CD45.2+ ETPs, DN2, and DN3 thymocytes in the absence of 
CD132 (γc) was examined in competitive BM chimeras, 8 weeks post-reconstitution. 
 
B) The development of CD45.2+ thymic granulocytes and cDC was examined in the same 
mice. 
 
C) The development of CD45.2+ splenic granulocytes and cDC was examined in the same 
mice. Two mice per group were examined.  
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Figure 2-1 Model: ETPs generate most adult thymic granulocytes 
 
 A myelo-lymphoid bone marrow progenitor settles the thymus using chemokine 
receptors CCR7 and CCR9. Under the influence of Notch signaling, thymus settling 
progenitors (TSP) expand to form the early thymic progenitor (ETP) population. ETPs 
give rise to T cells and thymic granulocytes (Gran). ETPs may give rise to some 
conventional dendritic cells (cDC), macrophages (Mac), and B cells in the thymus; 
however, these cells predominantly derive from non-ETP sources. Thymic 
granulocytes, like ETPs, depend on IL7Rα  for their development; however, it is unclear 
whether this requirement is pre-thymic, intrathymic, or both. 
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CHAPTER 3:  NOTCH-MEDIATED INHIBITION OF MYELOID 
DEVELOPMENT REQUIRES HES1 
 
3.1 Abstract 
 
 Notch signaling induces T cell lineage gene expression and discourages gene 
expression programs that promote alternative fates, such as B cells and myeloid cells.  
The mechanisms downstream of Notch that mediate T cell commitment by excluding 
alternative fate choices are not well understood. Here, we examine whether the Notch 
target and transcriptional repressor Hes1 is important for T-lineage commitment.  
Hematopoietic Hes1 deficiency results in severe T cell lineage defects; however, the 
underlying mechanism is unknown. Specifically, we hypothesized that Hes1 might 
inhibit myeloid fates in T cell progenitors, based on: 1) published work showing that 
Hes1 is sufficient to inhibit myelopoiesis and 2) our finding that ETPs access myeloid 
gene expression programs in vivo (Chapter 2). We found that Hes1 is necessary for 
Notch-mediated inhibition of myeloid, but not B cell potential, from multipotent 
progenitors in T-inductive conditions; however, in apparent conflict with these results, 
we did not observe any expansion of myeloid cells in the thymus of mice reconstituted 
with Hes1-deficient fetal liver (FL). Thus, we examined whether the consequences of 
Hes1 deficiency differ in multipotent versus lymphoid progenitors. In contrast to 
multipotent progenitors, Hes1-deficient lymphoid progenitor cells underwent apoptosis 
in T-inductive conditions and only adopted myeloid fates when supplemented with 
myeloid cytokines. Further, we found that lymphoid progenitors doubly deficient for 
Hes1 and TCF-1 generated expanded DC progeny in T-inductive conditions. These data 
suggest that: 1) the threshold for myeloid diversion is higher for lymphoid progenitors 
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compared to multipotent progenitors, and 2) that TCF-1 may prevent diversion of Hes1-
deficient lymphoid progenitors down the myeloid pathway.  
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3.2 Introduction 
 
Signaling via Notch receptors is essential for the generation of early T cell lineage 
progenitors (ETPs) in the thymus67,68. Notch signaling both upregulates T cell lineage 
specific gene expression and antagonizes alternative (non-T cell) fates as progenitor cells 
commit to the T cell lineage49,65,72,91,92,94,154.  ETPs retain the potential to develop into non-
T cell lymphoid cells (B cell and NK/ILCs), DCs and, to a degree, myeloid cells53,60,64–
67,83,88,89, in addition to robust potential to develop into T cells; however, the intrathymic 
mechanisms that repress alternative lineage programs are not well understood. 
Consequently, the importance of the repression of alternative fates for T cell 
development has not been clearly demonstrated. 
 
Hes1 is a basic helix-loop-helix (bHLH) transcriptional repressor and an 
evolutionarily conserved target of Notch signaling128. Germline deletion of Hes1 results 
in the absence of the thymus (in >90% of such mice) or a severely hypocellular thymus, 
in addition to defects in the pancreas, gut, bile duct, and neural tube that are lethal late 
in embryogenesis128,155,156.  The absence of a thymus in Hes1-deficient embryos may 
reflect defects in both hematopoietic cells and thymic stromal cells, because Hes1 is 
expressed in both cell types157. Hematopoietic cell–intrinsic expression of Hes1 is 
important for T cell development, and Hes1-deficient progenitor cells fail to generate 
normal numbers of T cells in competitive fetal liver (FL) or bone marrow (BM) chimeras 
or following direct intrathymic injection; however, the defect is not absolute156,158. It has 
been suggested that Hes1 facilitates T progenitor expansion, possibly via repression of 
Cdkn1b (which encodes the cell-cycle inhibitor p27Kip1) (refs. 158,159). 
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In Chapter 3, we investigate the hypothesis that Hes1 may repress gene 
expression important for the development of alternative lineage cells, such as B cells or 
myeloid cells during intrathymic T cell development. Hes1 is sufficient to inhibit B cell 
development94 and myeloid development (likely by repressing the critical myeloid 
transcription factor, C/EBPα) (refs. 8,72,73). The attenuation of myeloid potential in 
hematopoietic progenitor cells begins prethymically in FL and BM and results in the 
generation of IL-7Rα+ lymphoid progenitor cells, such as CLPs32,160. However, Hes1 is 
dispensable for the development of B cells and type 2 innate lymphoid cells (ILCs), 
which suggests it is not essential for extrathymic lymphoid specification83,156,158,161. As 
progenitor cells enter the thymus and experience strong Notch signals, myeloid gene 
expression programs may need to be actively repressed to allow T-lineage specification 
to proceed. Yet, perinatal lethality and the absence of a thymus in Hes1 germline 
knockout mice has precluded detailed analysis of thymus phenotypes156. Hence, it 
remains unknown whether the Hes1-deficient embryonic thymus has expanded numbers 
of non-T cell lineage cells, such as B cells or myeloid cells.  
 
Conditional deletion of Hes1 in BM progenitors using the interferon-inducible 
Mx1-Cre results in viable adult mice with an 80% reduction in thymic size and a 10-fold 
reduction in the absolute number of DN thymocytes158.  Intriguingly, deletion of Hes1 in 
DN3 and DN4 progenitors with Lck-Cre or CD4-Cre did not impair T cell development or 
thymic size158.  In this study, Hes1ΔMxCre BM progenitors developed into DP progenitors 
only when co-cultured with OP9-DL4 stromal cells, and not OP9-DL1. They instead 
found that Hes1ΔMxCre progenitors adopted an immature B cell fate (CD19+IgM–) in OP9-
DL1 cultures, which they suggest is due to the fact that the DL1 ligand provides a weaker 
binding avidity than DL4 (ref. 162).  However, Wendorff et al. failed to detect any 
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accumulation of B cells or myeloid cells in the thymi of Hes1ΔMxCre mice158. The failure of 
B cells to accumulate in the thymi of Hes1ΔMxCre mice is different from the phenotype of 
Notch-deficient mice72, indicating that mechanisms besides Hes1 exist to inhibit the B 
cell fate from ETPs. These results indicate that Hes1 is important before the DN3 stage of 
development/Β-selection checkpoint. This is consistent with a role for Hes1 in 
specification or commitment to the T cell lineage and the window of Hes1 expression (up 
to and including the DN3 stage).   
 
62 
 
3.3 Results 
3.3.1 Hes1 is essential for T cell lymphopoiesis 
 
 
We examined Hes1 expression in BM and thymic progenitor cells of wild-type 
adult mice by quantitative PCR. Adult ETPs and double-negative stage 2 (DN2) and DN3 
thymocytes had high expression of the Notch1 targets Hes1 and Dtx1 (which encodes the 
transcriptional regulator deltex-1), whereas those transcripts were low or absent in BM 
Lin–Sca-1+Kit+ (LSK) cells and lymphoid-primed multipotential progenitor cells (LMPP). 
We did not detect expression of Hes1 or Dtx1 mRNA in CD4+CD8+ double-positive 
thymocytes, consistent with the termination of Notch signaling after the B-selection 
checkpoint85. Common lymphoid progenitor cells (CLP)32 lacked Dtx1 expression but had 
low expression of Hes1 mRNA, perhaps because transcription factors such as E47 can 
induce Hes1 independently of Notch124.  
 
Expression of Cebpa followed a pattern that was reciprocal to that of Hes1 
(Figure 3-1). BM LSK and LMPP populations had high expression of Cebpa mRNA, 
which was downregulated in CLPs, consistent with the attenuated myeloid potential of 
those cells32. Cebpa expression was further reduced in ETPs and was almost completely 
extinguished in DN2 and DN3 thymocytes, in agreement with exposure to strong 
intrathymic Notch1 signals and correlating with upregulation of Hes1 expression. These 
data suggested that Hes1 may repress Cebpa in progenitor cells that have settled the 
thymus and are exposed to Notch1 ligands. 
 
The thymus was either absent or extremely hypocellular in Hes1-deficient (Hes1–
/–) embryos (Figure 3-2 A) which precluded detailed analysis of fetal thymocyte 
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populations156. Germline deletion of Hes1 is lethal perinatally, but we were able to assess 
FL progenitor cells and found similar frequencies of Lin–Kit+Flt3+ and CCR9+ progenitor 
cells in Hes1–/– FL and wild-type FL at embryonic days 14.5-16.5 (E14.5–E16.5) (Figure 
3-2 B). Thus, upregulation of the cytokine receptor fms-like tyrosine kinase receptor-3 
(Flt3) and the thymus settling chemokine receptor CCR9 were normal in the FL of Hes1-
deficient embryos.  
 
To determine the stage of T cell development that requires Hes1 in vivo, we 
generated competitive chimeras by mixing whole FL from Hes1–/– mice or their Hes1+/+ 
littermates with BM from adult host-type mice (at a ratio of 1:2, FL to BM) and 
intravenously injecting the mixture into lethally irradiated host mice. We examined the 
reconstitution of hematopoietic lineages in the recipients after 8–10 weeks, because we 
have found that this time point allows for reconstitution of ETPs in irradiation chimeras. 
The reconstitution of BM LSK cells was similar between mice that received Hes1–/– FL or 
Hes1+/+ control FL. However, the absence of Hes1 resulted in reduced ETP chimerism, 
and this defect became very pronounced by the DN2 stage83,158. The chimerism of DN2 
thymocytes from Hes1–/– cells was <2% that of BM chimerism (Figure 3-2 C). These data 
suggested to us that Hes1 may inhibit Cebpa expression during the ETP-to-DN2 
transition, since Cebpa expression is normally sharply downregulated by the DN2 stage 
of T cell development (Figure 3-1). Furthermore, Hes1–/– Lin–Kit+Flt3+ progenitor cells 
were defective in generating CD4+CD8+ DP T cells when mixed with host-type Hes1+/+ 
BM LSK competitor cells and directly injected into the thymus of sublethally irradiated 
congenic hosts  (Figure 3-2 D) as expected158, indicating that defective T cell 
development in the absence of Hes1 is not exclusively due to a thymic settling defect.  
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3.3.2 Notch constrains myeloid potential through Hes1 in multipotent 
progenitors 
 
 
To better examine the requirement for Hes1 during T cell development, we 
cultured  Hes1–/– Lin–Kit+Flt3+CCR9+ FL progenitor cells with OP9 stromal cells or OP9 
cells that express the Notch ligand Delta-like 4 (OP9-DL4) and stimulated the co-
cultures with the cytokines IL-7 (interleukin 7) and Flt3L (the ligand for the receptor 
tyrosine kinase Flt3). We chose this progenitor population because of its similar 
phenotype to the BM LMPP population and its expression of the thymus homing 
chemokine receptor, CCR961,134,163–166.  
 
We saw equivalent production of B cells and myeloid cells in OP9 cultures, as 
expected, since Hes1 is not upregulated in the absence of Notch ligands. In contrast, we 
observed striking differences between the genotypes when we cultured progenitors in the 
presence of Notch ligands, in OP9-Delta cultures. In T-inductive conditions, Hes1-
deficient progenitors generated a reduced number of T cell progeny and an expanded 
number of myeloid progeny  (Figure 3-3). We used limitng dilution analysis to determine 
that the frequency of T cell progenitors in the cultured population was reduced and the 
frequency of myeloid progenitors was increased (Figure 3-4). 
 
Indeed, we were able to determine that expression of several myeloid genes 
(Cebpa and Csf1r) failed to be downregulated in undifferentiated progenitors from OP9-
Delta cultures initiated with Hes1-deficient progenitors (Figure 3-5). Those data were 
consistent with expanded myeloid output from Hes1-deficient multipotent progenitors; 
however, expression of Sfpi1 (which encodes the transcription factor PU.1) was similar in 
cultures initiated with Hes1–/– progenitor cells and those initiated with Hes1+/+ control 
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progenitor cells. We also examined expression of Cdkn1b, which encodes the cyclin-
dependent kinase inhibitor p27Kip1 and is suggested to be a Hes1 target159,167; however, 
Cdkn1b expression was not upregulated in Mac1–CD25– cells from OP9-DL4 cultures 
initiated with Hes1–/– FL progenitor cells relative to its expression in those initiated with 
Hes1+/+ FL progenitor cells (Figure 3-5).  We were intrigued by these observations, and 
we wanted to investigate whether aberrant myeloid gene expression and/or increased 
myeloid progeny from Hes1-deficient progenitors in T-inductive conditions hampered 
their ability to efficiently generate T cells.  
 
We next wished to determine whether Hes1-deficient progenitors would generate 
increased amounts of myeloid progeny in vivo. To test this, we injected Hes1-deficient or 
littermate control FL progenitors (Lin–Kit+Flt3+CCR9+) directly into the thymi of 
sublethally irradiated congenic recipient mice and examined their contribution to 
myeloid populations in the thymus 6 days later. We found that Hes1-deficient 
progenitors generated more granulocytes than Hes1-heterozygous control progenitors 
(Figure 3-6). We did not observe an increase in generation of other myeloid cell types, 
such as DCs from Hes1-deficient progenitors.  Curiously, the generation of DCs, from 
Hes1-deficient progenitors was reduced (data not shown). This time point was not ideal 
for the examination of T-lineage cells, since these would take longer to develop, however, 
even at 6 days, we saw a decreased contribution of Hes1-deficient progenitors to CD25hi 
T-lineage thymocytes.  
 
Since the intrathymic injection experiment above required that we prospectively 
select a specific progenitor population, we decided to next use a mixed bone marrow 
chimera approach. This way, the thymus would “select” the settling progenitor cells. We 
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wanted to know whether myeloid cell types would expand in the thymus in the absence 
of Hes1, when the thymus was settled from circulating progenitors.  We generated mixed 
chimeras using Hes1-deficient FL progenitors.  After 8-10 weeks, we analyzed the 
chimeric mice for donor contribution to thymic and splenic populations. We chose this 
time point because we had previously found that this is a sufficient amount of time to 
allow ETPs to develop in irradiation chimeras. It was important to allow enough time for 
ETPs to develop, because we were particularly interested in examining myeloid lineage 
cells that may derive ETPs, such as thymic granulocytes83. We found that the 
contribution of Hes1-deficient cells to ETPs was decreased, as shown above (Figure 3-7 
A), and consistent with published work158. Further, contribution of Hes1-deficient cells to 
thymic granulocytes was also decreased (Figure 3-7 A); whereas, splenic granulocytes 
developed independently of Hes1 (Figure 3-7B). We additionally examined whether 
Hes1-deficiency affected the development of cDCs, macrophages, and B cells within the 
thymus, but found no significant defects in these lineages in the absence of Hes1 (Figure 
3-7.A, Figure 3-8).  
 
Based on the results of our OP9-Delta cultures and intrathymic injections, we 
were surprised to find that Hes1-deficient ETPs did not appear to generate increased 
numbers of myeloid cells in vivo in the thymus. Instead, thymic granulocytes (which we 
show primarily originate from ETPs in Chapter 2) appeared to be strongly Hes1-
dependent. These findings prompted us to re-evaluate the choice to use Lin–
Kit+Flt3+CCR9+ progenitors in the OP9-Delta cultures, and to refine this population 
further to attempt to obtain a more homogeneous lymphoid progenitor population that 
might recapitulate the results we saw in the thymus of mixed FL chimeras.  
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3.3.3 Lymphoid and multipotent progenitors respond differently to the 
absence of Hes1 
 
 
We examined the expression of the lymphoid cytokine receptor IL-7Rα within the 
Lin–Kit+Flt3+CCR9+ population and found that while a high percentage (~80%) of these 
cells were positive for IL-7Rα, there was a substantial fraction lacking this receptor 
(Figure 3-9). We considered that the heterogeneity of this population for IL-7Rα may 
have been confounded our results and decided to repeat the OP9-Delta cultures using 
Lin–Kit+Flt3+IL-7Rα+ lymphoid progenitors and IL-7Rα- multipotent progenitors. Given 
that BM MPP have robust myeloid potential, whereas CLPs have attenuated that 
potential32,160, we expected that the analagous FL populations may have different 
developmental potentials in vitro. We examined these populations in Hes1-deficient and 
littermate control FL at E12.5-13.5, and found them to be present at similar frequencies 
(Figure 3-10A)(ref. 168). We decided to eliminate the CCR9 marker from our studies, 
rather than using both CCR9 and IL-7Rα, in order to obtain a sufficiently large 
progenitor population for detailed studies.  
 
We first characterized the expression of Hes1, Dtx1, and Cebpa in these refined 
progenitor populations and in fetal thymocytes from wild type embryos (E12.5-13.5). 
Hes1 and Dtx1 were expressed in fetal DN2 thymocytes but had low or absent expression 
in FL progenitor cells and Mac-1+ myeloid cells (Figure 3-10 B). We detected low 
expression of Hes1 mRNA in FL lymphoid progenitor cells (Lin–Kit+Flt3+IL-7Rα+), 
analogous to BM CLPs. Cebpa expression was high in FL Lin–Kit+Flt3– and Flt3+IL-7Rα– 
multipotent progenitors (MPPs) and was downregulated in Flt3+IL-7Rα+ lymphoid 
progenitor cells. Cebpa expression was further diminished in fetal thymocytes, indicative 
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of a reciprocal relationship between Hes1 expression and Cebpa expression, consistent 
with our results in adult progenitors (Figure 3-1). 
 
We next wanted to determine whether downregulation of Cebpa occurred 
normally in the FL during lymphoid restriction in the absence of Hes1. Thus, we assessed 
Hes1 and Cebpa expression in FL cells and found that Cebpa was downregulated in 
Hes1–/– FL Lin–Kit+Flt3+IL-7Rα+ lymphoid progenitor cells relative to its expression in 
Hes1–/– FL Lin–Kit+Flt3+IL-7Rα– multipotent progenitor cells, to a similar degree 
compared to control progenitor cells (Figure 3-11). These results indicated that Hes1 was 
not necessary for downregulation of Cebpa expression in FL lymphoid progenitor cells 
before exposure to intrathymic Notch signals. Other transcription factors such as E2A 
that mediate lymphoid specification may fulfill this role124. 
 
To better examine the requirement for Hes1 during T cell development, we 
cultured  Hes1–/– lymphoid progenitors (Lin–Kit+Flt3+IL-7Rα+) and multipotent 
progenitors (Lin–Kit+Flt3+IL-7Rα–) with OP9 stromal cells or OP9-DL4 cells with IL-7 
and Flt3L. Hes1+/+ Lin–Kit+Flt3+IL-7Rα– multipotent progenitor cells generated mostly 
myeloid cells and few B cells in OP9 cultures, whereas Lin–Kit+Flt3+IL-7Rα+ lymphoid 
progenitor cells generated predominantly B cells and few myeloid cells. Hes1–/– FL MPP 
and lymphoid progenitor cells had developmental potential similar to that of their wild-
type counterparts in the absence of Notch signaling (Figure 3-12).  
 
In T-inductive conditions, the number of Thy1+CD25+ T-lineage progeny 
generated from either Hes1–/– multipotent progenitor cells or Hes1–/– lymphoid 
progenitor cells was much lower than that generated by wild-type progenitor cells 
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(Figure 3-13 A). At the time point examined (6 days) wild-type IL-7Rα+ lymphoid 
progenitors generated more T-lineage progeny than their IL-7Rα– multipotent 
progenitor counterparts, consistent with IL-7Rα expression marking a lymphoid 
specified progenitor that is developmentally downstream of an IL-7Rα– multipotent 
progenitors. Notch signaling effectively inhibited myeloid development from Hes1+/+ 
MPPs, while Hes1–/– MPP generated high numbers of Mac-1+ progeny, many of which co-
expressed Gr-1 (Figure 3-13 B). In contrast to Hes1–/– MPPs, Hes1–/– lymphoid 
progenitor cells generated very few Mac-1+ cells  (Figure 3-13 B).  
 
Notch-mediated inhibition of the B cell fate remained intact in Hes1–/– MPPs and 
lymphoid progenitor cells (Figure 3-14 A).  We hypothesized that in the absence of Hes1, 
other factors upregulated by Notch signaling, such as TCF-1 may be sufficient to inhibit 
the B cell fate. We decided to test whether Hes1 and TCF-1 were redundant for Notch-
mediated inhibition of B cell potential, so we generated mice doubly-deficient for Hes1 
and Tcf7 (the gene for TCF-1) and co-cultured FL progenitors from these mice and 
littermate controls with OP9-DL1 or OP9 stromal cells. Interestingly, Hes1–/–Tcf7–/– 
progenitors did not generate B cells in T-inductive conditions, but developed normally 
into B cells in OP9 cultures, in the absence of Notch signals (Figure 3-14 B).  These 
results indicate that other factors downstream of Notch, besides Hes1 and TCF-1, able to 
inhibit B cell potential. 
 
The fact that Hes1-deficient progenitors upregulate IL-7Ra normally in the FL 
(Figure 3-10) and generate B cells normally in OP9 cultures (Figure 3-12), suggests that 
lymphoid progenitors are generated normally and that T cell defects begin within the 
thymus, when progenitors are exposed to Notch signals and Hes1 expression is 
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upregulated (Figure 3-1). We decided to examine a recently identified population of Th2 
cytokine-producing innate lymphoid cells (ILC2) in the lungs of Hes1-deficient FL 
chimeras, since these cells have been shown to express Hes1 and other targets of Notch 
signaling (Figure 3-15 A) (ref. 161). We were intrigued to find that ILC2s in the lung did not 
depend on Hes1 for their development (Figure 3-15 B), despite the fact that these cells 
share many developmental requirements with T cells, such as TCF-1 and GATA-3 
dependence161,169–171. To date, we have not yet examined whether Hes1-deficient ILC2s 
have normal functional properties or whether Hes1 is required for the development of 
other types of ILCs, though we think these are worthwhile areas for further study. 
 
3.3.4 Hes1-deficient lymphoid progenitors generate expanded myeloid 
progeny in the presence of myeloid cytokines  
 
 
We were interested by the fact that Hes1-deficient lymphoid progenitors failed to 
generate enhanced myeloid progeny in T-inductive conditions, in contrast to multipotent 
progenitors that lacked Hes1.  Indeed, Hes1-deficient lymphoid progenitors generated 
fewer myeloid progeny than control progenitors in T-inductive conditions, and appeared 
to die.  Thus, lymphoid progenitors appeared to recapitulate the defect in ETP-derived 
thymic granulocytes in mixed chimeras using Hes1-deficient FL (Figure 3-7) (ref. 83). We 
found that Mac-1– Thy1– undifferentiated cells in OP9-DL4 cultures initiated with Hes1–
/– FL lymphoid progenitor cells showed more Annexin V staining than in cultures 
initiated with Hes1+/+ control lymphoid progenitor cells and decreased in number by day 
4 in the former cultures (Figure 3-16). After supplementation of OP9-DL4 cultures with 
myeloid cytokines (SCF, additional Flt3L, IL-3, M-CSF, GM-CSF and G-CSF), Hes1–/– FL 
lymphoid progenitor cells generated more Mac-1+ cells than did wild-type FL lymphoid 
progenitor cells (Figure 3-17). Mac-1+ cells generated from either Hes1+/+ or Hes1–/– 
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lymphoid progenitor cells were mainly Gr-1–CD11c+(Figure 3-17). These results indicated 
that Hes1 was required for Notch1-mediated inhibition of the development of myeloid 
cells, but not B cells, from MPPs. However, in contrast to Hes1–/– MPPs, Hes1–/– 
lymphoid progenitor cells did not readily divert to myeloid fates in T cell–inductive 
conditions, unless myeloid cytokines were provided.  
 
To investigate whether myeloid gene expression was affected by the absence of 
Hes1, we cultured Hes1–/– multipotent or lymphoid progenitor cells on OP9-DL4 stromal 
cells and isolated undifferentiated Mac-1–CD25– cells by cell sorting after 6 days for gene 
expression analysis. In our early studies using Hes1-deficient total Flt3+CCR9+ 
progenitors (a population heterogeneous for IL-7Rα expression), we had already found 
that expression of Cebpa and Csf1r failed to be downregulated in response to Notch 
signals.  In OP9-DL4 cultures, Cebpa expression was increased and Gata3 expression 
was decreased in Mac-1– Thy1–CD25– cells from cultures initiated with Hes1–/– Lin–
Kit+Flt3+IL-7Rα– MPPs compared to their Hes1+/+ counterparts (Figure 3-18), consistent 
with the expanded myeloid output from Hes1–/– MPPs. In similar conditions, we did not 
observe a difference between cells derived from Hes1–/– IL-7Rα+ Lin–Kit+Flt3+ cells and 
those derived from their Hes1+/+ counterparts in their Cebpa expression. In summary, 
these results suggested that multipotent and lymphoid progenitor cells responded 
differently to T cell–inductive Notch signals in the absence of Hes1: Hes1–/– MPPs 
exposed to Notch signals diverted to myeloid fates, whereas Hes1–/– lymphoid progenitor 
cells exposed to Notch ligands were unable to efficiently adopt either the T cell fate or 
myeloid cell fate and exhibited increased apoptosis. 
 
72 
 
3.3.5 Characterization of Hes1/TCF-1 doubly-deficient progenitors  
 
 
We hypothesized that other transcription factors induced by Notch, such as TCF-
1, might act redundantly with Hes1 to inhibit myeloid outgrowth from lymphoid 
progenitors.  The ability of TCF-1 to inhibit myeloid fates is unclear, though it appears to 
be less potent inhibitor of myeloid fates than Hes1 (ref. 92; De Obaldia, unpublished 
observations not shown here). To test this hypothesis, we sorted IL-7Rα+ Lin–Kit+Flt3+ 
lymphoid progenitors from FL doubly-deficient for Hes1 and TCF-1 or littermate control 
FL and co-cultured these cells with OP9 or OP9-Delta stromal cells and T-inductive 
cytokines. We saw expanded output of Mac1+Gr-1lo cells in T-inductive conditions from 
Hes1–/–Tcf7–/– lymphoid and multipotent progenitors progenitors relative to control 
Hes1+/+Tcf7+/+ or Hes1+/+Tcf7–/– progenitors (Figure 3-19). A Hes1–/– littermate control 
was not available for this experiment; however, based on historical controls (>5 
repetitions of the experiment shown in Figure 3-13), we never saw that Hes1–/– lymphoid 
progenitors generated expanded myeloid progeny in T-inductive conditions without 
provision of myeloid cytokines. Hes1+/+Tcf7–/– MPPs generated increased numbers of 
myeloid progeny in T-inductive conditions, and this effect was greatly exaggerated in 
Hes1–/–Tcf7–/– MPPs (Figure 3-19), indicating the importance of Hes1 for myeloid fate 
inhibition in MPPs.  These data, though preliminary, suggested to us that TCF-1 could 
prevent Hes1 lymphoid progenitors from adopting myeloid fates. 
 
Based on our finding that Hes1–/–Tcf7–/– lymphoid progenitors generated 
expanded myeloid progeny in T-inductive conditions, we wanted to determine whether 
Hes1–/–Tcf7–/– progenitors would generate expanded myeloid progeny in the thymus in 
vivo. Thus, we generated mixed FL chimeras using Hes1–/–Tcf7 FL or control FL 
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(Hes1+/+Tcf7+/+, Hes1+/+Tcf7–/–, or       Hes1–/–Tcf7+/+) and host-type competitor BM. After 
8-10 weeks, we analyzed the chimeric mice for donor contribution to thymic and splenic 
populations.  The contribution of Hes1–/–Tcf7–/– cells to ETPs was decreased relative to 
spleen granulocyte chimerism, which is a reliable index for BM LSK chimerism in these 
chimeras, which do not display myeloid lineage defects (Figure 3-20). In a side-by-side 
comparison, the defect in ETP chimerism in the absence of Hes1, or both Hes1 and TCF-1 
was much more severe than single deficiency in TCF-1, indicating that the requirement 
for Hes1 in early T cell development is likely to precede that of TCF-1 (Figure 3-20 ; 
Figure 3-22).  Progenitors deficient in either Hes1, TCF-1, or both factors showed a 
severe blockage in subsequent stages of T cell development (DN2 onwards) in 
competitive chimeras (Figure 3-20 ; Figure 3-22).  
 
Furthermore, the contribution of Hes1–/–Tcf7–/– cells to thymic granulocytes was 
also decreased; whereas, splenic granulocytes developed independently of Hes1 and 
TCF-1 (Figure 3-21). These results were similar to those seen with single Hes1-deficiency, 
and suggest that  Hes1–/–Tcf7–/– residual ETP do not generate expanded myeloid 
progeny. If they had, we would have expected the thymic granulocyte chimerism in these 
mice to be increased relative to the ETP donor chimerism. This assumption is based on 
our finding that most thymic granulocytes derive from ETPs in vivo, as indicated by the 
close correlation between ETP and thymic granulocyte chimerism observed in multiple 
experimental systems83. We additionally examined whether compound Hes1/TCF-1 
deficiency affected the development of cDCs, macrophages, and B cells within the 
thymus, but found no dramatic quantitative alterations in these lineages (Figure 3-21).    
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3.4 Discussion 
 
In this chapter, we investigated the nature of the T cell developmental defect in 
the absence of the canonical Notch target and basic helix-loop-helix transcriptional 
repressor Hes1. Hes1-deficient progenitor cells have a profound, but incomplete, 
developmental defect in the T cell lineage attributed to inadequate population expansion 
of early progenitor cells156,158; however, the precise cause of the defect has remained 
unknown. The absence of the thymus in 90% of Hes1-deficient embryos suggests that 
this severe defect may encompass both hematopoietic and thymic stromal cell defects, 
since both cell types express Hes1157. The Hes1 T cell defect was not exclusively due to 
impaired settling of the thymus, since Hes1-deficient FL progenitors showed defective T 
lymphopoiesis when directly injected into the thymus in the presence of congenically 
labeled wild-type progenitors or when co-cultured with OP9-Delta stromal cells.  
Interestingly, we observed that Hes1-deficient progenitors displayed a much less striking 
T cell defect upon intrathymic injection, when competitor cells were not included in the 
inoculum (data not shown).  
 
We, like other groups, have confirmed a hematopoietic cell-intrinsic role for Hes1 
during T cell development83,156,158. Hes1 deficiency results in about a 50% defect in donor-
derived ETPs in mixed FL chimeras, relative to the percentage of donor BM engraftment. 
We observed no difference between Hes1-deficient and wild-type control FL in their 
ability to engraft the BM of lethally irradiated hosts.  The T cell developmental defect in 
the absence of Hes1 became much more severe at the DN2 stage of thymocyte 
development.  Our data suggest that C/EBPα may need to be downregulated for T cell 
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specification to proceed, consistent with the observed decrease in Cebpa mRNA as 
thymocytes progressed from ETPs to DN2 progenitors. 
 
We observed that Hes1 is necessary for Notch-mediated inhibition of myeloid 
potential in multipotent progenitors. Because Hes1 robustly inhibits Cebpa expression 
and myeloid potential94,130,172, we examined whether the absence of Hes1 resulted in 
inappropriate myeloid-lineage gene expression and myeloid development from 
progenitors cultured in T-inductive conditions.  We found that Notch failed to inhibit 
myeloid development and myeloid gene expression from Hes1-deficient FL multipotent 
progenitors (MPPs) in T-inductive conditions. Additionally, injection of Hes1-deficient 
MPPs into the thymus of sublethally irradiated hosts resulted in expanded myeloid 
granulocyte progeny.  These observations led us to hypothesize that the T cell 
developmental defect in the absence of Hes1 may be due to either 1) diversion of 
progenitors from the T cell pathway to generate myeloid progeny at the expense of T cell 
progeny, or 2) that aberrant myeloid gene expression may interfere with the T cell 
developmental program.   
 
If defective T cell development in the absence of Hes1 caused T cell progenitors to 
divert towards myeloid fates preferentially, then we would expect to see an increased 
contribution of Hes1-deficient donor cells to myeloid cells in the thymus of mixed 
chimeras. However, we never saw enhanced generation of myeloid cells in the thymus of 
Hes1-deficient progenitors in mixed FL chimeras.  Instead, thymic granulocytes were 
strongly Hes1-dependent and diminished in these chimeras, consistent with our data 
that these cells predominantly derive from ETPs83.   This finding was intriguing to us for 
several reasons, discussed in detail below. Briefly, it suggested that 1) thymic 
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granulocytes developed from a progenitor that had experienced some degree of Notch 
signaling, and 2) it prompted us to refine the multipotent progenitor population used in 
our in vitro studies to more closely reflect the in vivo situation.  
 
The first reason relates directly to the work described in Chapter 1, by which we 
found that ETPs access myeloid fates in vivo. Notch and Hes1 are known to be sufficient 
to inhibit myeloid development49,65,94,101,154,172. Thus, it has been proposed that ETPs may 
give rise to non-T-lineage cells instead of becoming T cells when they “escape” strong 
Notch signals. However, we found that thymic granulocytes were diminished in the 
absence of Hes1. These data show that thymic granulocytes develop from a progenitor 
that requires Hes1, like T cell precursors, but unlike extrathymic granulocytes.  This 
suggests to us that Notch and Hes1 are required in order to generate ETPs in the first 
place, and by extension thymic granulocytes. Thus, thymic granulocytes derive from a 
progenitor that has experienced Notch signals to some extent.  Then, following initial 
exposure to Notch ligands (and Hes1 upregulation), some ETPs may enter 
microenvironments protected from Notch signals that are thus more permissive for the 
generation of myeloid progeny.  Indeed, the thymus contains regions that lack high 
expression of examined Notch ligands76,173.   
 
The biological significance of myeloid potential in the ETP population is unclear. 
Myeloid lineage cells in the thymus are important for the phagocytosis of negatively 
selected immature T cells; however, these cells would not necessarily have to derive from 
T cell progenitors, but could instead may migrate into the thymus as mature myeloid 
cells or as myeloid progenitor cells.  Another possibility is that the myeloid potential of 
ETPs is a rather  “unintentional” consequence of a stem/progenitor cell “legacy” 
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transcriptional program inherited from upstream BM progenitors, which confers T cell 
progenitors with tremendous proliferative capacity87. Moreover, elements of the T cell 
developmental program, such as Gfi1, are both expressed by ETPs174 and are involved in 
neutrophil fate specification175. Thus, it is possible that components of the early T cell 
developmental program allow and perhaps even potentiate the granulocyte fate from 
some uncommitted progenitors.  
 
Why should this be the case? One idea is that the generation of granulocytes from 
ETPs allows for factors that promote myeloid development and inhibit proliferation, 
such as the critical myeloid regulator C/EBPα, to be diluted out by T-lineage progenitors 
as they proliferate176. This would be consistent published work showing that ectopic 
expression of myeloid transcription factors in DN thymocytes conferred a survival 
disadvantage in T-inductive conditions177,178. Consistently, ETPs with higher C/EBPα 
expression (as identified in a reporter mouse strain) are less efficient progenitor cells of 
T cells than are those with lower C/EBPα expression179. It is possible that myeloid 
transcription factors or factors that inhibit the effects of Notch (such as Numb) are 
segregated asymmetrically in dividing ETPs, resulting in the formation of thymic 
granulocyte and ETP daughter cells. In this way, development of thymic granulocytes 
from ETPs, could indirectly facilitate T cell development by diluting out myeloid 
transcription factors that would otherwise inhibit T-lineage specification.  
 
Secondly, the discord between aberrant myelopoiesis from Hes1-deficient MPPs 
cultured in T-inductive conditions and the absence of similar myeloid expansion in the 
thymus in the absence of Hes1 motivated us to refine the progenitor population used in 
our in vitro studies. We wished to identify a more homogenous population of lymphoid 
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progenitors that would recapitulate our in vivo data. Importantly, we found that the 
consequences of Hes1 deficiency differed substantially between MPPs and lymphoid 
progenitor populations. Hes1-deficient MPPs displayed a developmental bias toward 
generation of myeloid cells and DCs after Notch signaling, even in the absence of 
exogenous myeloid cytokines; however, Hes1-deficient lymphoid progenitor cells 
underwent apoptosis in the same conditions unless myeloid cytokines were provided. 
Thus, our results indicated that the threshold for myeloid diversion of lymphoid 
progenitor cells was higher than that for diversion of multipotent progenitor cells after 
Notch signaling in vitro. Our results are consistent with published work showing that 
ectopic expression of myeloid transcription factors in DN thymocytes conferred a 
survival disadvantage in T-inductive conditions177,178. These data may also explain why 
diversion of Hes1-deficient T cell progenitor cells to myeloid fates is not apparent in the 
thymus of FL chimeras83,158.  
 
Our observations help explain the sequential loss of alternative lineage potentials 
during early T cell development. We propose that the main function of Hes1 during T cell 
development may be to constrain myeloid gene expression programs, an idea which we 
directly test in work described in Chapter 5 of this thesis. Hes1 is no longer expressed 
after the DN3 stage, which indicates that additional mechanisms are probably needed to 
silence myeloid genes in committed progenitors of T cells and mature T cells.  
Specifically, the transcriptional regulator Bcl11b may constrain myeloid potential after 
the ETPs stage, as it only begins to be expressed in DN2 thymocytes and is sufficient to 
inhibit Cebpa expression95,96. The ability of TCF-1 to inhibit myeloid fates appears to be, 
if anything, much less robust than that of Hes1 (De Obaldia ME, unpublished 
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observations); however, it is possible that residual myeloid potential in Hes1-
experienced cells can be kept in check by TCF-1 and/or other factors.  
 
Interestingly, Hes1 was not required for the inhibition of B cell fate, a process 
that is probably mediated by multiple Notch effectors acting in concert (such as TCF-1, 
GATA-3, and others)91,92. Indeed, Notch inhibited the B cell fate even in progenitors 
deficient in both Hes1 and TCF-1. Thus, our data are consistent with the idea that 
multiple mechanisms act together to inhibit different non-T cell lineage programs in 
early T cell progenitors. This idea has been borne out by analysis of sequential T cell 
progenitor populations by ChIP and deep sequencing, which revealed that diverse 
histone modifications mark different genes encoding hematopoietic regulatory molecules 
across development22. 
  
 In Chapter 5, we next examine in more detail the mechanism by which Hes1 
inhibits myeloid programs and examine whether the essential role of Hes1 in early T cell 
development is to constrain myeloid programs or whether additional mechanisms exist. 
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3.5 Figures 
 
 
 
  
 
 
Figure 3-1 Hes1 expression is upregulated in the thymus 
  
Quantitative PCR (qPCR) of Hes1 mRNA expression in adult bone marrow (BM) LSKs, 
LMPPs, CLPs and thymic ETPs, DN2s, DN3s, and DP progenitor populations isolated by 
cell sorting from C57/BL6 mice. Data are normalized to Gapdh. Error bars represent SEM 
of triplicate wells. Results shown represent three separate experiments. ND: not 
determined. 
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Figure 3-2 Hes1 is required for T cell development in vivo 
 
A) Photographs of Hes1−/− or Hes1+/+ embryos and flow cytometry of fetal thymi (E15.5)  
 
B) Flow cytometry of FL from Hes1−/− or Hes1+/+ control embryos (E15.5) 
 
C) Flow cytometry of mixed irradiation chimeras made by intravenously injecting a mixture of 
either CD45.2+ Hes1−/− or Hes1+/+ littermate control FL (E15.5) and competitor CD45.1+ BM. 
Recipient mice were examined 8-10 weeks post reconstitution.  
 
D) Flow cytometry of thymus from CD45.1+ recipient mice injected intrathymically with a 
mixture of CD45.2+ FL progenitors (Lin−Kit+Flt3+) sorted from Hes1−/− or Hes1+/+ littermate 
control embryos (15.5 dpc) and sorted CD45.1+ BM progenitors (Lin−Sca1+Kit+Flt3+) and 
intrathymically injected into sublethally irradiated CD45.1+ recipient mice. Recipient mice were 
examined 17 days post-injection. 
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Figure 3-3 Notch fails to inhibit myelopoiesis from FL MPPs in the absence of 
Hes1 
 
A) Flow cytometry of OP9-DL4 or OP9 cultures initiated with 250 FL Lin-Kit+Flt3+CCR9+ 
progenitors sorted from Hes1−/− or Hes1+/+ littermate control embryos (E15.5). Cultures were 
harvested after 6 days to assay for the presence of myeloid cells, T cells, or B cells. Results are 
representative of three independent experiments. 
 
B) Shown are the absolute numbers of CD25+ T lineage cells, Mac1+ myeloid cells, or CD19+ 
cells analyzed per well (as tabulated in the Methods).  
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Figure 3-4 Hes1-deficient MPPs show decreased T cell and increased myeloid 
progenitor frequency 
 
A) Limiting dilution analysis of Lin−Kit+Flt3+CCR9+ FL from Hes1−/− or littermate control 
embryos, co-cultured with OP9-DL4 stromal cells in the presence of IL-7 and Flt3L. The 
frequency of progenitors that generated Mac-1+Gr-1+ granulocytes was determined as 
described in the Methods. 
B) Same as in A), except the frequency of progenitors that generated Thy1+CD25+ T lineage 
progeny was determined as described in the Methods. 
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Figure 3-5 Notch fails to downregulate myeloid genes in MPPs lacking Hes1 
 
Flow cytometry of OP9-DL4 cultures using FL progenitors (Lin-Kit+Flt3+CCR9+) sorted 
from Hes1−/− or Hes1+/+ littermate control embryos (E15.5). After 6 days, Mac1-CD25- cells 
were sorted for qPCR analysis. Shown are mean mRNA expression levels normalized based 
on Gapdh levels. 
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Figure 3-6 Following intrathymic injection, Hes1-deficient MPPs generate 
expanded myeloid progeny in vivo 
 
FL progenitors  (Lin-Kit+Flt3+CCR9+) from Hes1−/− or Hes1+/−  littermate control embryos 
(E15.5) were intrathymically injected into sublethally irradiated CD45.1+ recipient mice. 
Donor contribution to Mac1+Gr-1+ thymic granulocytes was analyzed at 6 days post-
injection. Shown are the mean percentages +SEM of donor CD45.2+ cells contributing to 
CD25hi T lineage cells and Mac1+Gr-1+ thymic granulocytes. Data are representative of 
one experiment with n=4 embryos for each genotype, and n=6 recipient mice in each 
group. Data were analyzed using a two-sided t-test: *p<0.05, ***p<0.001 
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Figure 3-7 Thymus granulocytes and DCs are not expanded in Hes1-deficient FL 
chimeras 
 
A) The development of CD45.2+ thymic ETPs, granulocytes, and cDC was examined in the 
absence of Hes1 in mixed FL chimeras, 8-10 weeks after reconstitution of lethally irradiated 
CD45.1+ hosts . Shown is the mean percent CD45.2+ donor contribution to each intrathymic 
lineage by Hes1+/+ (black bars) or Hes1−/−  (gray bars) FL. Four mice per group were examined. 
***p<0.001 for the CD45.2+ donor chimerism of the indicated population compared with BM 
LSK CD45.2+ donor chimerism.  
 
B) The development of CD45.2+ BM LSKs, splenic granulocytes, and cDC was examined in the 
absence of Hes1 in mixed FL chimeras, 8-10 weeks after reconstitution of lethally irradiated 
CD45.1+ hosts. Shown is the mean percentage CD45.2+ donor contribution to each lineage by 
Hes1+/+ (black bars) or Hes1−/−  (gray bars) FL. Four mice per group were examined. Error bars 
represent SEM. 
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Figure 3-8 Thymus macrophages and B cells are not expanded in Hes1-deficient FL 
chimeras 
 
A) The development of CD45.2+ thymic macrophages and B cells was examined in mixed FL 
chimeras, 8 weeks after reconstitution of lethally irradiated CD45.1+ hosts.   
B) Shown is the mean percent CD45.2+ donor contribution to each intrathymic population by 
Hes1+/+ (black bars) or Hes1−/−  (gray bars) FL. Error bars represent SEM. Four mice per group 
were examined.   
 
C) The development of CD45.2+ splenic macrophages and B cells was examined in mixed FL 
chimeras, 8-10 weeks after reconstitution of lethally irradiated CD45.1+ hosts.   
 
D) Shown is the mean percent CD45.2+ donor contribution to each splenic population by Hes1+/+ 
(black bars) or Hes1−/−  (gray bars) FL. Four mice were examined per group. Error bars represent 
SEM.  
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Figure 3-9 CCR9+ FL MPPs are heterogeneous for IL-7Rα  expression 
 
Flow cytometry of FL from Hes1−/− or Hes1+/+ control embryos (E15.5) to examine expression of 
IL-7Rα and the thymus homing chemokine receptor CCR9.  
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Figure 3-10 Characterization of FL lymphoid progenitors 
 
A) Flow cytometric analysis of Hes1–/– or Hes1+/+ littermate control FL (E12.5-13.5). FACS plots 
shown represent three separate experiments.  
 
B) qPCR of Hes1 mRNA expression in fetal liver (FL) MPPs, lymphoid progenitors, GMPs, Mac-
1+ cells  and DN2 fetal thymocytes collected at E12.5-13.5 from C57/BL6 embryos. Data are 
normalized to Gapdh levels. Results shown represent three separate experiments. 
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Figure 3-11 Hes1-deficient FL lymphoid progenitors effectively 
downregulate Cebpa expression 
 
A) qPCR analysis of Hes1 expression in FL progenitor populations isolated by cell 
sorting from Hes1–/– embryos or Hes1+/+ littermate control embryos (E12.5-13.5). 
Hes1+/+ fetal thymocyte progenitors (E13.5) were used as a comparator population. 
Data are normalized to Gapdh levels. Results shown represent n=2 Hes1–/– FL and 
n=1 Hes1+/+ FL. UD: undetected. ND: not determined. 
 
B) Same as in A), except expression of Cebpa was examined. ND: not determined. 
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Figure 3-12 Hes1-deficient FL progenitors generate B cells and myeloid cells 
normally 
 
A) Flow cytometric analysis of FL progenitors (Lin–Kit+Flt3+ IL-7Rα– or IL-7Rα+) isolated by cell 
sorting from Hes1–/– or Hes1+/+ littermate control embryos (E12.5-13.5), cultured with OP9 
stromal cells (250 cells per well in triplicate) and harvested after 6 days. Shown are representative 
FACS plots from one of three similar experiments. 
 
B) Shown are the mean numbers of CD19+ B cells or Mac1+ myeloid cells analyzed per well 
(details in the Methods).  
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Figure 3-13 Hes1-deficient MPPs (but not lymphoid progenitors) generate 
expanded myeloid progeny in T-inductive conditions 
 
A) Flow cytometric analysis of FL progenitors (Lin–Kit+Flt3+ IL-7Rα– or IL-7Rα+) isolated by 
cell sorting from Hes1–/– or Hes1+/+ littermate control embryos (E12.5-13.5), cultured with 
OP9-DL4 stromal cells (250 cells per well, in triplicate) and harvested after 6 days. Shown are 
representative FACS plots from one of three similar experiments.  Shown are average numbers 
of Thy-1+CD25+ cells analyzed per well (details in Methods). Error bars represent SEM. 
*p<0.05. 
B) Same experiment as in A), except the development of Mac-1+Gr-1+ cells in these wells was 
examined. Shown are average numbers of Thy-1+CD25+ cells analyzed per well (details in 
Methods). Error bars represent SEM. *p<0.05, **p<0.01. 
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Figure 3-14 Notch continues to inhibit B cell potential in the absence of Hes1 and TCF-1 
 
A) Flow cytometric analysis of FL progenitors (Lin–Kit+Flt3+ IL-7Rα– or IL-7Rα+) from Hes1–/– or 
Hes1+/+ littermate control embryos (E12.5-13.5), cultured with OP9-DL4 stromal cells (250 cells per 
well in triplicate) and harvested after 6 days. Shown are representative FACS plots from one of three 
similar experiments. 
 
B) Flow cytometric analysis of FL lymphoid progenitors (Lin–Kit+Flt3+ IL-7Rα+) from    Hes1–/– Tfc7–
/–  or littermate control embryos (E12.5-13.5), cultured with OP9-DL4 stromal cells (250 cells per well 
in triplicate) and harvested after 6 days. Shown are representative FACS plots from one experiment 
performed in triplicate. 
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Figure 3-15 Hes1 is not necessary for lung ILC2 development 
 
A) BM multipotent progenitors (MPP: LSK Flt3+), lung ILC2 cells, and DN3 
thymocytes were sorted from C57/BL6 mice and gene expression was examined by 
qPCR.  
 
B) Flow cytometry of mixed irradiation chimeras made by intravenously injecting a 
mixture of either CD45.2+ Hes1−/− or Hes1+/+ littermate control FL (E15.5) and 
competitor CD45.1+ BM.  Development of CD45.2+ donor-derived lung ILC2s, BM 
LSKs, and splenic CD3+ T cells were examined 8 weeks post reconstitution. Shown is 
the mean percentage of donor lung ILC2 chimerism normalized to the BM LSK 
chimerism. Data are representative of two experiments in which at least 5 mice per 
group were examined. ns=not significant.   
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Figure 3-16 Hes1-deficient lymphoid progenitors undergo apoptosis in T-
inductive conditions lacking myeloid cytokines 
 
A) Flow cytometric analysis of FL multipotent progenitors (Lin–Kit+Flt3+IL-7Rα–) or 
lymphoid progenitors (Lin–Kit+Flt3+IL-7Rα+) isolated by cell sorting from Hes1–/– or Hes1+/+ 
littermate control embryos (E12.5-13.5), cultured with OP9-DL4 stromal cells (500 cells per 
well in triplicate) and harvested after 4 days. FACS plots are representative of three similar 
experiments. 
B) Same experiment as in A) Shown are the mean percentages of Mac-1–Thy-1–DAPI– cells 
that were Annexin V+.  Numbers represent a fraction of the total well (as described in 
Methods). Data are representative of two similar experiments. Error bars represent SEM. 
*p<0.05, **p<0.01.  
 
C) Same experiment as in A) Shown are the mean numbers of DAPI–Mac-1–Thy-1– cells 
analyzed per well (details in the Methods). Data are representative of two similar 
experiments.  Error bars represent SEM. *p<0.05. 
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Figure 3-17 Hes1-deficient lymphoid progenitors generate expanded myeloid 
progeny when OP9-Delta cultures are supplemented with myeloid cytokines 
 
A) Flow cytometric analysis of FL multipotent progenitors (Lin–Kit+Flt3+IL-7Rα–) or lymphoid 
progenitors (Lin–Kit+Flt3+IL-7Rα+) isolated by cell sorting from Hes1–/– or Hes1+/+ littermate 
control embryos (E12.5-13.5), cultured with OP9-DL1 stroma (250 cells per well in triplicate) 
with IL-7, Flt3L, and myeloid cytokines (IL-3, SCF, additional Flt3L, M-CSF, GM-CSF, G-CSF- 
details in Methods) and harvested after 6 days. FACS plots are from one experiment performed 
in triplicate using a range of myeloid cytokine doses. Results were similar and showed dose-
responsiveness across a 10-fold range of cytokine doses tested.  
 
B) Same experiment as in A). Shown are average numbers of Mac-1+CD11c+ cells analyzed per 
well. Error bars represent SEM. **p<0.01. 
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Figure 3-18 Hes1-deficient MPPs fail to downregulate Cebpa expression in the 
presence of Notch 
 
Flow cytometric and qPCR analysis of FL multipotent progenitors (Lin–Kit+Flt3+IL-7Rα–) or 
lymphoid progenitors (Lin–Kit+Flt3+IL-7Rα+) isolated by cell sorting from Hes1–/– or Hes1+/+ 
littermate control embryos (E13.5) and cultured with OP9-DL4 stromal cells.  After 6 days, 
the indicated Mac-1–Thy-1–CD25– population was isolated by cell sorting for qPCR analysis. 
Shown are average mRNA expression levels normalized to Gapdh levels. Data are 
representative of at least two similar experiments. Error bars represent SEM. ***p<0.001. 
98 
 
 
 
Figure 3-19 Hes1/TCF-1 deficient lymphoid progenitors generate expanded 
myeloid progeny in T-inductive conditions 
 
A) Lymphoid progenitors Lin–Kit+Flt3+IL-7Rα+) isolated by cell sorting from Hes1–/– Tcf7–/– 
or littermate control embryos (E13.5) were cultured with OP9-DL4 or OP9 stromal cells for 6 
days (500 cells/well).  
 
B) Shown are the relative numbers of Mac-1+Gr-1lo cells analyzed per well, normalized to the 
Hes1+/+ Tcf7+/+ control. Data are representative of one experiment performed in triplicate.  
Error bars represent SEM. *p<0.05; **p<0.01.  
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Figure 3-20 Early T cell development is abrogated in Hes1/TCF-1 double-deficient 
FL chimeras 
 
A) The development of CD45.2+ BM LSK, thymic ETP, DN2, DN3, and DP thymocytes was 
examined in the absence of Hes1 and TCF-1 in mixed FL chimeras, 8-10 weeks after 
reconstitution of lethally irradiated CD45.1+ hosts. 
B) Shown is the mean percent CD45.2+ donor contribution to each lineage by donor FL of the 
indicated genotypes. Three mice per group were examined. Error bars represent SEM. *p<0.05, 
**p<0.01, ***p<0.001 for the CD45.2+ donor chimerism of the indicated population compared 
with spleen granulocyte CD45.2+ donor chimerism. Note: The Hes1 ETP defect does not achieve 
statistical significance in this experiment because of scatter in BM reconstitution (indicated by 
spleen Mac1+Gr-1+ chimerism). 
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Figure 3-21 Thymic myeloid cells are not expanded in Hes1/TCF-1 double-
deficient FL chimeras 
 
A) The development of CD45.2+ spleen granulocytes, thymic granulocytes, thymic cDC 
subsets, and thymic CD19+ B cells was examined in the absence of Hes1 and TCF-1 in 
mixed FL chimeras, 8-10 weeks after reconstitution of lethally irradiated CD45.1+ hosts. 
Note that CD8α and Mac1 are expressed on distinct populations of cDCs, and CD8α+ cDCs 
were gated as Mac1- cDCs in this experiment. 
 
B) Shown is the mean percent CD45.2+ donor contribution to each lineage by donor FL of 
the indicated genotypes. Three mice per group were examined. Error bars represent SEM.  
*p<0.05, **p<0.01, ***p<0.001 for the CD45.2+ donor chimerism of the indicated 
population compared with spleen granulocyte CD45.2+ donor chimerism. Note: The Hes1 
thymic granulocyte defect does not achieve statistical significance in this experiment 
because of scatter in BM reconstitution (indicated by spleen Mac1+Gr-1+ chimerism). 
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Figure 3-22   Hes1 defect precedes TCF-1 defect in intrathymic T cell 
development 
 
The development of CD45.2+ spleen granulocytes, T lineage thymocyte progenitors, thymic 
granulocytes, cDC subsets, and CD19+ B cells was examined in the absence of Hes1 and TCF-1 
in mixed FL chimeras, 8-10 weeks after reconstitution of lethally irradiated CD45.1+ hosts. 
Shown is the mean percent CD45.2+ donor contribution to each lineage by donor FL of the 
indicated genotypes. Three mice per group were examined. Error bars represent SEM.  
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CHAPTER 4:  THE ESSENTIAL FUNCTION OF HES1 IS TO CONSTRAIN 
C/EBPα-DEPENDENT MYELOID PROGRAMS 
 
4.1 Abstract 
 
Notch signaling induces expression of T-lineage genes and antagonizes gene 
expression associated with alternative lineages. Hematopoietic deficiency in the Notch 
target and transcriptional repressor Hes1 results in severe T cell lineage defects; 
however, the underlying mechanism is unknown. In Chapter 2, we established that ETPs 
access myeloid gene expression programs and fates in vivo. Then in Chapter 3, we 
showed that Hes1 is required for Notch-mediated inhibition of myeloid development 
from multipotent progenitors.  In Chapter 4, we investigate in more detail the 
mechanism of action of Hes1 during T cell development. We also investigate how Hes1 
inhibits myeloid development and whether the essential role of Hes1 during T cell 
development is to inhibit myeloid fates, or whether there are likely to be additional 
mechanisms.  We found that Hes1 is likely to directly repress the critical myeloid 
regulator C/EBPα. Hes1 was bound to the Cebpa promoter in DN3 thymocytes and 
further, it was able to inhibit the Cebpa promoter in a luciferase reporter assay. 
Repression of Cebpa by Hes1 required its DNA-binding and WRPW Groucho-interaction 
domains.  We found that the essential and perhaps only role of Hes1 during T cell 
development is to constrain myeloid gene expression programs, since deletion of 
C/EBPα completely restored T cell development from Hes1-deficient progenitors. 
Importantly, Cebpa deletion rescued T cell development in Hes1-deficient multipotent 
progenitors and lymphoid progenitors alike, indicating that misexpression of Cebpa 
inhibits T cell development, even in the absence of overt diversion to myeloid fates. Our 
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findings establish the critical importance of constraining developmental programs of the 
myeloid lineage early in T cell development.  
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4.2 Introduction 
 
In Chapter 4, we investigate in more detail the mechanism of action of Hes1 
during T cell development. We investigate how Hes1 inhibits myeloid development and 
whether the essential role of Hes1 during T cell development is to inhibit myeloid fates, 
or whether there additional mechanisms are involved.  Germline deletion of Hes1 results 
in many developmental defects, such as the absence of the thymus (in >90% of such 
mice) or a severely hypocellular thymus, in addition to pancreas, gut, bile duct and 
neural tube defects that are lethal late in embryogenesis128,155,156.  These defects each 
reveal a common role for Hes1 in the maintenance of undifferentiated progenitors157. 
Hes1 is required for the maintenance of neural precursors and the common precursors of 
pancreatic exocrine and endocrine cells. Consequently, loss of Hes1 results in severely 
compromised brain and pancreas morphogenesis. In both cases, the absence of Hes1 
causes a multipotent precursor to differentiate prematurely into one lineage, rather than 
proliferating and giving rise to multiple complementary cell types155,157,180.  
 
The absence of a thymus in Hes1-deficient embryos may reflect defects in both 
hematopoietic cells and thymic stromal cells, because Hes1 is expressed in both cell 
types157. Hematopoietic cell–intrinsic expression of Hes1 is important for T cell 
development, and Hes1-deficient progenitor cells fail to generate normal numbers of T 
cells in competitive FL or BM chimeras or following direct intrathymic injection; 
however, the defect is not absolute156,158. It has been suggested that Hes1 facilitates T 
progenitor expansion, possibly via repression of cell cycle inhibitors158,159. Indeed, Hes1 
has been shown to facilitate proliferation in cell lines via repression of Cdkn1b159, which 
encodes the cyclin-dependent kinase inhibitor p27kip1. Hence, Hes1 has described roles in 
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proliferation and progenitor maintenance; however, the precise role of Hes1 in T cell 
progenitors remains unclear. 
 
Several studies suggest an antagonistic relationship between Hes1 and C/EBPα, a 
critical regulator of the development of myeloid cells136 and DCs181 as well as 
adipogenesis131. Ectopic expression of Hes1 inhibits myelopoiesis from BM progenitor 
cells94,172. Furthermore, during mast cell development, Notch2 signaling upregulates the 
expression of Gata3 (which encodes the transcription factor and T cell regulator GATA-
3) and Hes1, which is thought to repress the gene encoding C/EBPα (Cebpa) and prevent 
diversion of mast cell progenitor cells to other myeloid fates130,182. Because T cell 
progenitors express high levels of Hes1, we considered that Hes1 may constrain C/EBPα 
and perhaps other myeloid factors early in T cell development. 
 
The attenuation of myeloid potential in hematopoietic progenitor cells begins 
prethymically in FL and BM and results in the generation of IL-7Rα+ lymphoid 
progenitor cells32,160. However, Hes1 is dispensable for the development of B cells, which 
suggests it is not essential for extrathymic lymphoid specification31,68,75. As progenitor 
cells enter the thymus and experience strong Notch signals, myeloid gene expression 
programs may need to be actively repressed to allow specification to the T cell lineage to 
proceed. Ectopic C/EBPα expression in CD4–CD8– double-negative (DN) thymocytes 
experiencing Notch signaling inhibits survival and subsequent T cell development178. 
Consistently, ETPs with higher C/EBPα expression (as identified in a reporter mouse 
strain) are less efficient T cell progenitors than are those with lower C/EBPα 
expression179.   
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Hes1 is a mammalian homologue of Drosophila hairy and Enhancer of split127. 
Hes1 is a basic helix-loop-helix (bHLH) transcriptional repressor and an evolutionarily 
conserved target of Notch signaling128.  There are at least five Hes family members, all of 
which are bHLH factors.  The HLH domain of Hes1 allows it to form homodimers or to 
heterodimerize with other HLH factors157. Hes proteins are unique among bHLH factors, 
in that they have a conserved proline region in their basic (DNA binding) domain. It is 
thought that this proline residue causes Hes proteins to bind only to N-box sequences 
(CACNAG) with high affinity, as opposed to E-box sequences (CANNTG), which they 
bind only with low affinity127. Hes1 also features an α-helical stretch called the “orange 
domain”, which may provide an additional protein interaction interface and was shown 
to function as a transcriptional repressor when joined to a DNA-binding domain183. The 
carboxy-terminus of Hes1 features a WRPW domain, which interacts with Groucho 
homologues TLE1-4 to form a transcriptional repressor complex131,184. Affinity 
purification of Hes1 from mouse preadipocytes revealed few interaction partners 
including TLE 1,3, and 4 (ref. 131).   Groucho/TLE is then thought to recruit histone 
deacetylase (HDAC) corepressors and other members of the Sin3 complex185,186. It has 
been suggested that Hes1 requires sirtuins, such as SIRT1, in addition to HDACs for full 
repression activity187. HDAC1 is thought to bind the bHLH domain and the C-terminus of 
Hes factors, while SIRT1 only binds the the bHLH domain187–189.  Thus, more work 
remains to be done to clarify mechanisms of repression by Hes proteins. 
 
Generally speaking, it is thought that Hes1 can enact transcriptional repression in 
one of two ways: either by complexing with Groucho co-repressors and directly binding 
to N-box sequences, or by heterodimerizing with positive bHLH factors, effectively 
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sequestering them and preventing them from binding E-boxes and activating 
transcription127. These mechanisms are referred to as “active” or “passive” repression, 
respectively (Figure 4-2). An important distinction between these two mechanisms, is 
that DNA binding is presumably only required for “active” repression. In Chapter 4, we 
attempt to discriminate between these two potential modes of Hes1-mediated 
repression. 
 
We found that Hes1 appears to directly repress C/EBPα in a manner dependent 
on its DNA binding and Groucho-interaction domains. Futhermore, we conclude that 
constraint of myeloid gene expression programs appears to be the major, and perhaps 
only role of Hes1 during early T cell development. This is because deletion of the myeloid 
regulator C/EBPα eliminated the requirement for Hes1 during T cell development in 
vitro and in vivo. Importantly, Cebpa deletion rescued T cell development in Hes1-
deficient multipotent progenitors and lymphoid progenitors alike, even though the 
consequences of Hes1 deficiency appear to differ quite substantially, as we showed in 
Chapter 3. These data indicate that misexpression of Cebpa can inhibit T cell 
development, even in the absence of overt diversion to myeloid fates. Thus, constraint of 
conflicting myeloid gene expression programs by Hes1 is a critical prerequisite for the 
specification and commitment of T cells. 
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4.3 Results 
4.3.1 Hes1 represses Cebpa expression 
 
We studied how ectopic expression of Hes1 in hematopoietic progenitor cells 
resulted in downregulation of Cebpa. We treated C57BL/6 mice with the 
chemotherapeutic agent 5-fluorouracil (5-FU) to enrich for HSCs, collected BM from 
those mice, retrovirally transduced the BM with vector encoding human Hes1 or empty 
vector and injected the BM intravenously into irradiated host mice. In this system, 
expression of green fluorescent protein (GFP) is used to track transduced cells. We used 
cell sorting to isolate GFP+ BM LSK progenitor cells from mice reconstituted with BM 
transduced with the Hes1-encoding vector or empty vector and analyzed gene expression 
by qPCR. Ectopic expression of Hes1 resulted in downregulation of Cebpa in BM LSK 
progenitor cells, consistent with published studies94,130,172 (Figure 4-1 A). Hes1 
overexpression did not affect the expression of Sfpi1 or Cdkn1b (Figure 4-1 B), consistent 
with our loss-of-function data and published data190. To determine whether Hes1 affects 
the expression of C/EBPα protein, we retrovirally transduced the 32D mouse myeloid 
cell line with Hes1-encoding vector or empty vector and isolated transduced cells after 48 
h by cell sorting according to GFP expression. Immunoblot analysis indicated that cells 
transduced with the Hes1-encoding vector had less C/EBPα protein than did those 
transduced with empty vector (Figure 4-1 C). 
 
Hes1 inhibits gene expression via direct DNA binding and recruitment of 
Groucho corepressors via its carboxy-terminal Trp-Arg-Pro-Trp (WRPW) domain. 
However, Hes1 can also inhibit gene expression by heterodimerizing with positively 
acting bHLH transcription factors and decreasing their affinity for activating E-box sites, 
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a repressive mechanism that presumable does not require DNA binding by Hes1 (Figure 
4-2). To discriminate between those mechanisms, we transduced wild-type Lin–Kit+Flt3+ 
FL progenitor cells with retrovirus encoding a mutant human Hes1 construct lacking the 
DNA-binding domain or one lacking the WRPW domain104.  We confirmed in 3T3 cells 
that Hes1 protein was expressed similarly between WT and mutant Hes1 constructs 
using intracellular flow cytometry for Hes1 protein (Figure 4-3 A). We isolated transduced 
GFP+ cells by cell sorting 48 h later and analyzed gene expression by qPCR. Wild-type 
Hes1 repressed Cebpa expression in Lin–Kit+Flt3+ FL progenitor cells, whereas neither 
Hes1 mutant was able to do so (Figure 4-3 B). We also assessed the ability of the mutant 
Hes1 constructs to support T cell development and inhibit myeloid development. 
Expression of wild-type Hes1 in Hes1–/– progenitor cells restored T cell development and 
suppressed myelopoiesis in OP9-DL4 cultures, as expected; however, expression of the 
Hes1 mutants was not able to do so. Transduction with retrovirus encoding the mutant 
Hes1 lacking the DNA-binding domain neither rescued T cell development nor inhibited 
myelopoiesis in OP9-DL4 cultures (Figure 4-3 C). Transduction with retrovirus encoding 
the mutant Hes1 lacking the WRPW domain led to some T cell development in OP9-DL4 
cultures; however, this was much lower than that resulting from transduction of 
retrovirus encoding wild-type Hes1 (Figure 4-3 D). These results suggested that DNA 
binding and interaction with Groucho proteins were important for Hes1-mediated 
inhibition of Cebpa expression and Hes1 function. 
 
Analysis of the mouse Cebpa promoter revealed several putative Hes1-binding 
(N-box) sites (Figure 4-4 A), which suggested a role for Hes1 in directly regulating this 
gene. A Hes1-binding site 165 base pairs upstream of the Cebpa transcriptional start site 
is bound by Hes1 in 32D cells172. Chromatin immunoprecipitation (ChIP) showed 
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enrichment for Hes1 binding at the site 165 upstream but not at another site 1.2 kilobases 
upstream of the transcriptional start site (TSS) in DN3 thymocytes (Figure 4-4 B). Hes1 
also bound to its own promoter in DN3 thymocytes, consistent with Hes1 
autoregulation192, but did not bind a negative control site (Figure 4-4 B). Moreover, Hes1 
repressed the activity of a luciferase reporter containing Cebpa promoter, and mutation 
of the Hes1-binding site in the reporter abolished that effect (Figure 4-5). These data 
suggested that Hes1 may directly bind the Cebpa promoter and repress its transcription 
in progenitors of T cells through interaction with Groucho corepressors. 
 
4.3.2 Deletion of C/EBPα  restores T cell lymphopoiesis in the absence of 
Hes1 in vitro and in vivo 
 
To determine whether the primary role of Hes1 in T cell development is to repress 
Cebpa expression or related myeloid gene expression programs, we investigated whether 
deletion of C/EBPα would restore the development of T cells from Hes1-deficient 
progenitor cells. C/EBPα is necessary for the development of myeloid cells, but not T 
cells (Figure 4-6) (ref. 136). We generated Hes1+/– mice with loxP-flanked Cebpa alleles 
(Cebpafl/fl)193 and then intercrossed those mice to obtain Hes1–/–Cebpafl/fl embryos. To 
delete C/EBPa, we transduced FL Lin–Kit+Flt3+ multipotent progenitor cells from Hes1–
/–Cebpafl/fl or Hes1+/–Cebpafl/fl embryos (at E15.5) with retroviral vector encoding Cre 
recombinase and GFP (MSCV-Cre-GFP; called 'Cre-GFP' here) and cultured both the 
resulting Cre-GFP+ (transduced) and Cre-GFP– (untransduced) fractions on OP9-DL4 
stromal cells. The development of myeloid cells from Cre-GFP+ Hes1–/–Cebpafl/fl and Cre-
GFP+ Hes1+/–Cebpafl/fl progenitor cells was completely abrogated (Figure 4-7 A), 
consistent with published data41,106. Both Cre-GFP+ and Cre-GFP– Hes1+/–Cebpafl/fl 
progenitor cells robustly produced T cell populations on OP9-DL4 cells, as was expected, 
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since C/EBPα is not required for T cell development20. In similar cultures, only Cre-GFP+ 
Hes1–/–Cebpafl/fl progenitor cells gave rise to robust populations of CD25+ T-lineage cells, 
while Cre-GFP– Hes1–/–Cebpafl/fl cells generated mostly Mac-1+ myeloid cells and very 
few T cells (Figure 4-7 A). These data indicated that deletion of C/EBPα restored the T 
cell potential of Hes1–/– progenitor cells. Further, they established that the effects of 
C/EBPα deletion were cell autonomous. 
 
To quantify the effect of the deletion of C/EBPα in Hes1–/– progenitor cells, we 
transduced Hes1–/–Cebpafl/fl Lin–Kit+Flt3+ FL progenitor cells with Cre-GFP or with an 
empty retroviral vector encoding GFP (referred to here as empty vector), cultured them 
on OP9-DL4 stromal cells, and examined the cultures by flow cytometry after 7 days. 
Significantly more CD25+ T cells were generated by Hes1–/–Cebpafl/fl progenitor cells 
transduced with Cre-GFP than by those transduced with empty vector (Figure 4-8 B), We 
also assessed Cre-GFP+ progenitor cells in OP9-DL4 cultures by limiting-dilution 
analysis. Although the frequency of T cell progenitors among transduced cells was lower 
than that among untransduced cells (data not shown), the frequency of T cell progenitors 
was similar among Cre-GFP+ Hes1–/–Cebpafl/fl cells (1/43) and Cre-GFP+ Hes1+/+Cebpafl/fl 
cells (1/56), and both of those frequencies were significantly higher than that of Hes1–/–
Cebpafl/fl cells transduced with empty vector (1/170) (Figure 4-8 ). Thus, deletion of 
C/EBPα substantially improved the generation of T cells from Hes1–/– progenitor cells. 
Collectively, these data were consistent with the idea that T cell development requires 
Hes1-mediated repression of Cebpa and perhaps related myeloid genes. 
 
Next we determined whether deletion of C/EBPα would restore the development 
of T cells from Hes1–/– thymus-settling progenitor cells in vivo. We bred Hes1+/–Cebpafl/fl 
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mice with Vav1-Cre mice, which results in specific expression of Cre recombinase in 
hematopoietic cells194. We bred the resulting Hes1+/–Cebpafl/+Vav1-Cre mice with Hes1+/–
Cebpafl/fl mice to obtain Hes1–/–Cebpafl/flVav1-Cre embryos. We mixed whole FL from 
Hes1–/–Cebpafl/flVav1-Cre embryos (at E15.5) or their littermates (Hes1+/–Cebpafl/flVav1-
Cre or Hes1–/–Cebpafl/+Vav1-Cre) with CD45.1+ wild-type adult BM and transplanted the 
mixture into lethally irradiated CD45.1+ recipient mice. T cell development in mice 
reconstituted with Hes1–/–Cebpafl/flVav1-Cre progenitor cells was restored to wild-type 
levels (Figure 4-9 A,C). As an additional control, we did not detect Hes1 mRNA in DN3 
thymocytes derived from Hes1–/–Cebpafl/flVav1-Cre cells  (Figure 4-9 B).  We determined 
that Hes1–/–Cebpafl/flVav1-Cre FL reconstituted all stages of T cell development 
normally, in a manner indistinguishable from control Hes1-sufficient progenitors (Figure 
4-10). The controls used in these experiments were either Hes1+/–Cebpafl/flVav1-Cre cells 
or Hes1+/–Cebpafl/+Vav1-Cre cells, and we saw normal development of T cells from cells 
of both those genotypes in vivo (data not shown). 
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4.3.3 Deletion of C/EBPα  in Hes1-deficient FL restores T cell lymphopoiesis 
from both multipotent and lymphoid progenitors 
 
Because Hes1–/– MPPs and lymphoid progenitor cells had different 
developmental potential in OP9-DL4 cultures, we assessed the effect of deletion of 
C/EBPα in each Hes1–/– progenitor cell type in vitro. We cultured Lin–Kit+Flt3+IL-7Rα– 
multipotent progenitor cells or Lin–Kit+Flt3+IL-7Rα+ lymphoid progenitor cells from 
Hes1–/–Cebpafl/flVav1-Cre embryos or their Hes1+/–Cebpafl/+Vav1-Cre littermates with 
OP9-DL4 stromal cells and examined T cell development by flow cytometry. The 
development of T cells from either Hes1–/– MPPs or lymphoid progenitor cells was 
restored to wild-type levels by deletion of C/EBPα (Figure 4-11). These results suggested 
that failure to downregulate myeloid lineage gene expression prohibited T cell 
development, even in the absence of overt myeloid diversion. These findings 
demonstrated that deletion of the myeloid factor C/EBPα eliminated the requirement for 
Hes1 in T cell development in vivo. 
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4.4 Discussion 
 
To investigate the mechanism and importance of alternative lineage gene 
repression during early T cell development, we focused on the canonical Notch target 
and bHLH transcriptional repressor Hes1. Hes1-deficient progenitor cells have a 
profound, but incomplete, developmental defect in the T cell lineage attributed to 
inadequate population expansion of early progenitor cells156,158; however, the precise 
cause of the defect has remained unknown. Because Hes1 robustly inhibits Cebpa 
expression and myeloid potential94,130,172, we investigated whether the major role of Hes1 
during early T cell development is to constrain myeloid lineage gene expression 
programs, or whether there are other mechanisms. We found that deletion of C/EBPα in 
Hes1-deficient progenitor cells restored in vivo T cell development to wild-type levels. 
Hence, our results establish that the main, and perhaps only, role of Hes1 in T cell 
development is to inhibit myeloid gene expression programs. 
 
Our results suggest that C/EBPα must be downregulated for T-lineage 
specification to proceed, consistent with the observed decrease in Cebpa mRNA as 
thymocytes progressed from ETPs to DN2 progenitors. As shown in Chapter 3, the 
consequences of Hes1 deficiency differed in MPP and lymphoid progenitor populations. 
Hes1-deficient MPPs displayed a developmental bias to generate myeloid cells and DCs 
after Notch signaling, even in the absence of exogenous myeloid cytokines, whereas 
Hes1-deficient lymphoid progenitor cells underwent apoptosis in the same conditions. 
Additionally, our results indicated that the threshold for myeloid diversion of lymphoid 
progenitor cells was higher than that for diversion of multipotent progenitor cells after 
Notch signaling in vitro, because in our studies it required the provision of myeloid 
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cytokines. Our results are consistent with other published work showing that ectopic 
expression of myeloid transcription factors in DN thymocytes conferred a survival 
disadvantage in T-inductive conditions177,178. These data may also explain why diversion 
of Hes1-deficient T cell progenitor cells to myeloid fates is not apparent in the thymus of 
FL chimeras83,158. Notably, the deletion of C/EBPα restored the development of both 
Hes1-deficient MPPs and Hes1-deficient lymphoid progenitor cells into T cells, which 
indicated that failure to constrain myeloid lineage gene expression inhibits T cell 
development even in the absence of overt diversion to the myeloid lineage. 
 
Our work and that of others172 suggests that Hes1 directly represses Cebpa, 
because the Hes1 DNA-binding domain is necessary for inhibition of C/EBPα and Hes1 
binds to the Cebpa promoter in DN3 thymocytes. Furthermore, Hes1 may rely on 
Groucho corepressors for its function184, as alteration of the carboxy-terminal WRPW 
Groucho interaction domain greatly decreased Hes1 function. Although our data suggest 
that Hes1 represses Cebpa directly in T cell progenitors, Hes1 may also act on other 
effectors in the same pathway. 
 
Our observations help explain the sequential loss of alternative lineage potentials 
during early T cell development. We propose that the main function of Hes1 during T cell 
development is to constrain myeloid gene expression programs. Hes1 was not required 
for the inhibition of B cell fate, a process that is probably mediated by other Notch 
effectors (such as TCF-1 and GATA-3)91,92. The transcriptional regulator Bcl11b may 
constrain myeloid potential after the ETP stage, as it is expressed in DN2 thymocytes 
and inhibits Cebpa expression95,96. Consistent with the idea that biochemically and 
temporally distinct mechanisms act together to inhibit non-T cell lineage programs, 
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analysis of sequential T cell progenitor populations by ChIP and deep sequencing has 
revealed that diverse histone modifications mark different genes encoding hematopoietic 
regulatory molecules across development22. In FL-derived DN1 cells cultured with Notch 
ligands22 and in wild-type ETPs, DN2 and DN3 thymocytes (our unpublished data), the 
Cebpa TSS was bivalently marked with the activating histone marks H3K4me3 or 
H3K(9,14)Ac, as well as the repressive mark H3K27me3, which suggests that repression 
had initiated in at least some cells. Hes1 is no longer expressed after the DN3 stage, 
which indicates that additional mechanisms are probably needed to silence myeloid 
genes in committed progenitors of T cells and mature T cells. Because progenitor cells 
lacking Cebpa and Hes1 generated normal numbers of T cells, they may be a useful 
reagent with which to delineate stage-specific mechanisms by which regulators of the 
myeloid lineage are initially constrained and finally silenced during T cell development. 
 
Our data support a model in which Notch signals upregulate expression of the 
transcriptional repressor Hes1 shortly after entry into the thymus, coincident with the 
generation of ETPs. Hes1 directly inhibits Cebpa expression and perhaps that of other 
myeloid lineage genes, which remain accessible in early thymus settling progenitor cells 
and ETPs83. Thus, our findings establish the importance of constraining developmental 
programs of the myeloid lineage early in intrathymic T cell development, a task 
accomplished by inclusion of Hes1 in the gene-regulatory network that establishes T cell 
identity. 
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4.5 Figures 
 
Figure 4-1 Hes1 inhibits myeloid Cebpa mRNA and protein expression 
 
A) qPCR analysis of BM LSKs harvested from mice reconstituted with MigR1- or HES1-
transduced 5-FU treated BM 8 weeks earlier. qPCR data are normalized to 18S. Error bars 
represent SEM.  
B) qPCR analysis of BM LSK cells transduced with MigR1 or HES1 48 hours earlier. qPCR data 
are normalized to Gapdh. Error bars represent SEM. 
C) Immunoblotting for C/EBPα in 32D cells transduced with HES1 or MigR1 control vector 48 
hours earlier. GFP+ cells were isolated by cell sorting prior to lysis. 
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Figure 4-2 Potential modes of Hes1-mediated gene repression 
 
A) Shown are the domains of Hes1 protein, including: a basic domain that mediates DNA 
binding, a helix-loop-helix (HLH) domain important for dimerization, an α-helical stretch 
called the orange domain thought to serve as a protein interaction interface and which may 
be important for repressor function, and a C-terminal WRPW domain important for 
interaction with Groucho/TLE co-repressor proteins. 
 
B) Hes1 may “actively” repress gene expression via direct DNA binding to an N-box 
sequence in the target gene promoter via its basic domain and recruitment of Groucho 
corepressors via its carboxy-terminal Trp-Arg-Pro-Trp (WRPW) domain.   
 
C) Hes1 may also inhibit gene expression “passively” by complexing with positively acting 
bHLH transcription factors and decreasing their affinity for activating E-box sites, a 
repressive mechanism that presumably does not require DNA binding by Hes1. 
 
Model adapted from Kageyama et al, 2000, Mol. Cells. 
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Figure 4-3 Repression of Cebpa requires DNA binding and Groucho interaction 
domains of Hes1 
 
A) Flow cytometry to assess Hes1 protein expression in 3T3 cells transduced with WT HES1 or 
mutant HES1 retrovirus. 
 
B) qPCR analysis of Cebpa expression in Hes1+/+ FL progenitors (Lin–Kit+Flt3+) (E15.5) transduced 
with MigR1, wild-type (WT) HES1, DNA binding mutant HES1 (HES1ΔDNA bind.), or Groucho 
interaction mutant HES1 (HES1ΔGroucho int.) 48 hours earlier. Data are normalized to Gapdh 
expression. 
 
C) Flow cytometric analysis of OP9-DL4 cultures using Hes1–/– FL (Lin–Kit+Flt3+) (E15.5) 
transduced with MigR1, WT HES1 or HES1ΔDNA bind. retrovirus. Cultures were harvested after 8 
days. Plots are gated on GFP+ cells. 
 
D) Similar experiment as in C) except HES1ΔGroucho int. mutant was used. 
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Figure 4-4 Hes1 binds mouse Cebpa promoter in DN3 thymocytes 
 
A) The mouse Cebpa promoter contains two N-box sites where Hes1 may be able to bind. 
The N-box consensus sequence is CACNAG, where N may be any amino acid. 
 
B) Chromatin Immunoprecipitation (ChIP) for Hes1 binding to the Cebpa promoter using 
Rag1-deficient thymocytes (enriched for DN3 thymocytes). Hes1 binding to the Hes1 and 
Nanog promoters was also examined, as a positive and negative control, respectively. 
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Figure 4-5 Hes1 inhibits mouse Cebpa promoter activity 
 
Luciferase reporter assay using 293T cells cotransfected with a luciferase construct containing Cebpa 
promoter sequence including one Hes1 binding site (Cebpa prom) or a mutated Hes1 binding site 
(Cebpa prom ΔHes1 site) and with either MigR1 or HES1-GFP. Luciferase activity is shown relative 
to Renilla luciferase and normalized to empty vector. Data are averages of triplicate wells. Error bars 
represent standard deviation. Results represent 3 independent experiments. ***p<0.001, NS= not 
significant. 
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Figure 4-6 C/EBPα  is necessary for myeloid development 
 
Flow cytometric analysis of irradiation chimeras made by intravenously injecting irradiated CD45.1+ 
mice with a mixture of FL (E15.5) from Cebpafl/flVav1-Cre or Cebpafl/fl embryos and CD45.1+ BM 10-
12 weeks earlier. Results represent two independent experiments.  
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Figure 4-7 Cebpa deletion restores T lineage competence to Hes1-deficient 
progenitors in vitro 
 
A) Flow cytometric analysis of OP9-DL4 cultures using FL multipotent progenitors (Lin–
Kit+Flt3+) (E15.5) that were isolated by cell sorting from Hes1–/–Cebpafl/fl or Hes1+/–
Cebpafl/fl control embryos and retrovirally transduced with MSCV-Cre-GFP. Cultures were 
analyzed after 7 days.  
 
B) Flow cytometric analysis of OP9-DL4 cultures using Hes1–/–Cebpafl/fl FL (E15.5) 
progenitors (Lin–Kit+Flt3+) transduced with MigR1 control vector or MSCV-Cre-GFP 
retrovirus and sorted for GFP expression. Cultures were analyzed after 7 days. Shown is the 
average number of CD25+ T cells analyzed on the cytometer (as described in Methods). Data 
are normalized to the number of GFP+ cells plated. Error bars represent SEM. *p<0.05. 
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Figure 4-8 Cebpa deletion restores T cell progenitor frequency in Hes1-
deficient progenitors 
 
A) Limiting dilution analysis to determine T cell progenitor (Thy1+CD25+) 
frequency in OP9-DL4 cultures of Hes1–/–Cebpafl/fl or Hes1+/+Cebpafl/fl FL 
progenitors (Lin–Kit+Flt3+) (E15.5) transduced with MigR1 control vector or MSCV-
Cre-GFP retrovirus, and sorted for GFP expression. Cultures were analyzed by flow 
cytometry after 6 days. 
B) Representative wells from the OP9-DL4 cultures described above. 
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Figure 4-9 Cebpa deletion restores in vivo T cell development from Hes1-deficient 
progenitors 
 
A) Flow cytometric analysis of irradiation chimeras made by intravenously injecting irradiated 
CD45.1+ mice with a mixture of FL (E15.5) from Hes1–/–Cebpafl/flVav1-Cre, Hes1–/–Cebpafl/+Vav1-
Cre, or Hes1+/–Cebpafl/flVav1-Cre embryos and CD45.1+ BM 10-12 weeks earlier. Results 
represent two independent experiments.  
 
B) qPCR analysis of CD45.2+ FL-derived DN3 thymocytes sorted from mice reconstituted with 
Hes1–/–Cebpafl/flVav1-Cre FL to verify absence of Hes1 mRNA. Hes1+/+ DN3 cells were a positive 
control. UD:undetected.  
 
C) Average numbers of CD45.2+ donor-derived thymocytes per chimeric mouse. Three mice were 
examined per group, except the Hes1–/–Cebpafl/+Vav1-Cre group for which one mouse was 
examined. Data are from one of two similar experiments. 
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Figure 4-10 Cebpa deletion restores all stages of in vivo T cell development from 
Hes1-deficient progenitors 
 
A) Flow cytometry of hematopoietic lineages in mixed FL chimeras made by intravenously 
injecting a mixture of CD45.2+Hes1–/–Cebpafl/flVav1Cre, Hes1–/–Cebpafl/+Vav1Cre, orHes1+/–
Cebpafl/flVav1Cre FL and CD45.1+ competitor BM cells into CD45.1+ lethally irradiated recipient 
mice. After 8-10 weeks, the CD45.2+ donor contribution to each population was assessed. 
 
B) Average percentage CD45.2+ donor chimerism of the indicated populations in mixed FL 
chimeras made as described in A). BM chimerism was inferred from CD19+ splenic B cell 
chimerism. The numbers of chimeric mice examined were: 6 Hes1–/–Cebpafl/flVav1-Cre, 5 Hes1+/– 
Cebpafl/+Vav1-Cre or Cebpafl/flVav1-Cre, and 2 Hes1–/–Cebpafl/+Vav1-Cre. Equivalent T cell 
development was seen between mice reconstituted with Hes1+/– Cebpafl/+Vav1-Cre and Hes1+/–
Cebpafl/flVav1-Cre progenitors, so these groups were pooled. Data represent two independent 
experiments.  
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Figure 4-11 Cebpa deletion restores T cell development from both lymphoid and 
multipotent progenitors 
 
Flow cytometric analysis of OP9-DL1 cultures using FL multipotent progenitors (Lin–Kit+Flt3+IL-
7Rα–) or lymphoid progenitors (Lin–Kit+Flt3+IL-7Rα+) from Hes1–/–Cebpafl/flVav1-Cre or Hes1+/–
Cebpafl/flVav1-Cre embryos (E13.5). Cultures were analyzed after 6 days. Shown are the average 
Thy-1+CD25+ cell numbers analyzed on the cytometer (see Methods for details). Data represent two 
similar experiments. 
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Figure 4-12 Model: Hes1 constrains myeloid gene expression programs during early T 
cell development 
 
Early thymic progenitors (ETP) develop under the influence of Notch signaling in the thymus. 
Shortly after thymic entry, Notch induces the expression of the transcriptional repressor Hes1, which 
directly inhibits C/EBPα, a critical myeloid regulator and perhaps other myeloid lineage genes. Hes1 
is expressed in CD4/CD8 double-negative (DN) thymocytes, including ETP, DN2, and DN3 
progenitors, but is no longer expressed at the CD4/CD8 double-positive (DP) stage. DN3 and DP 
thymocytes are committed to the T-cell lineage. 
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CHAPTER 5:  DISCUSSION/FUTURE DIRECTIONS 
 
5.1 Summary of findings 
 
We have established that ETPs are bona fide multipotent progenitors, since they 
generate both T cell and granulocyte progeny in the thymus in vivo (Chapter 2). Based 
on these findings, we hypothesized that myeloid gene expression programs need to be 
constrained early in T cell development. We hypothesized that the Notch target and 
transcriptional repressor Hes1 may fulfill this role, since its expression is sufficient to 
inhibit a critical regulator of myeloid development, C/EBPα. Hematopoietic Hes1 
deficiency severely abrogates T cell development; however, the precise function of Hes1 
has remained unclear. We show in Chapter 3 that Notch requires Hes1 to inhibit myeloid 
development from multipotent progenitors, since Hes1-deficient multipotent progenitors 
generate increased numbers of myeloid progeny in T-inductive conditions. In contrast, 
Hes1-deficient lymphoid progenitors only generate expanded myeloid progeny in T-
inductive conditions when myeloid cytokines are also provided. In Chapter 4, we 
examine the mechanism of Hes1 function in greater detail, and find that it binds to the 
Cebpa promoter in DN3 thymocytes. Finally, we found that the essential function of 
Hes1 during T cell development is to constrain myeloid gene expression programs in 
early T cell progenitors. This follows from our finding that deletion of C/EBPα, a critical 
myeloid transcription factor, eliminates the requirement for Hes1 during T cell 
development. Thus, our work has established that early T cell progenitors access myeloid 
developmental programs in vivo and emphasizes the critical importance of constraining 
myeloid gene expression programs in the thymus. 
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5.2 Key implications of this work 
 
1. Many physiological thymus settling progenitors (TSPs) likely express IL-7R at 
functional levels and retain the ability to access myeloid gene expression 
programs. 
2. Thymic granulocytes are generated predominantly from Hes1-dependent 
ETP/DN2 thymocytes, unlike many other alternative lineage cells in the thymus. 
3. Hes1-dependent ETPs (those which generate thymic granulocytes in vivo) are 
responsible for most T cell development. 
4. Distinct mechanisms inhibit myeloid programs in BM CLPs (Hes1-independent) 
versus thymus (Hes1-dependent).  
5. Lineage-specific mechanisms to inhibit myeloid potential likely exist, since 
ILC2s, which use many elements of the core T cell program (TCF-1, GATA-3) 
develop independently of Hes1. 
6. Multiple mechanisms exist to constrain different lineage potentials in 
uncommitted, intrathymic T cell progenitors. Protracted access to myeloid gene 
expression programs may reflect an association between these programs and 
stem/progenitor programs that drive robust T cell progenitor expansion. 
7. Failure to inhibit myeloid programs in the absence of Hes1 causes defective in 
vivo T cell development from physiological TSPs. Cebpa deletion rescues Hes1 T 
cell developmental defect from both lymphoid progenitors and multipotent 
progenitors in vitro. 
 
 
131 
 
5.2.1  Many physiological TSPs likely express IL-7R at functional levels and 
retain the ability to access myeloid gene expression programs 
 
 
Clarification of the pathways that contribute to T cell development will allow for 
the construction of more complete models of hematopoietic differentiation.  Briefly, 
studies showing that ETPs retain myeloid potential long after they extinguish B cell 
potential have challenged the idea that there is an early, obligate segregation of myeloid 
and lymphoid potentials in the BM64–67. Furthermore, understanding the developmental 
potentials and gene regulatory networks of the earliest T cell progenitors may inform our 
understanding of oncogenic transformation, since failure to appropriately silence 
stem/progenitor gene expression is linked to T-ALL development87. Despite intensive 
efforts to understand the properties of in vivo thymus settling progenitors (TSPs), this 
has remained a confusing issue (described in more detail in section 1.1 of the 
Introduction). Indeed, it has been extensively debated whether most T cells arise from 
TSPs within the IL-7R+ CLP population, the mostly IL-7R– LMPP population, or perhaps 
cells from both compartments. We think our work provides important new insights into 
this issue.  
 
The cell surface phenotype of ETPs has been used to predict the phenotype of 
TSPs. Specifically, ETPs resemble LMPPs, in that both populations express high levels of 
Kit, and most cells in the population appear to lack surface IL-7Rα expression. This 
shared phenotype is distinct from that of CLPs, which express low levels of Kit and are 
unambiguously IL-7Rα+(ref. 63). Recent work using an IL-7R/Cre lineage tracing 
approach found that close to 90% of pro-T cells (Lin–Kit+CD25-CD44+, a population 
which includes ETPs) were labeled with a developmental history of IL-7Rα expression53. 
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The authors of this study argue that these data indicate that ETPs derive from CLPs, 
which are about 80% labeled in IL-7R/Cre mice.  However, we consider that these data 
do not exclude the possibility that ETPs originate from LMPPs, even though only about 
10% of LMPPs are labeled in IL-7R/Cre mice53. 
 
 Indeed, we believe there are several reasons to think that ETPs derive from 
progenitors that both express functional levels of IL-7R on their surface and retain the 
ability to access myeloid gene expression programs.  
 
First, our finding that development of ETPs is severely abrogated in the absence 
of either IL-7Rα or common γ-chain, suggests that many TSPs express functional levels 
of the IL-7R and/or that TSPs rapidly become dependent on IL-7R signaling after taking 
residence in the thymus83.  These two possibilities are quite difficult to dissect, and may 
require the development of new stage-specific deletion strategies.  
 
Secondly, we believe that our work on the role of Hes1 during early T cell 
development supports the idea that many TSPs have functional levels of IL-7R on their 
surface. Briefly, our in vitro studies revealed that only IL-7Rα– progenitors from Hes1-
deficient FL generate expanded myeloid progeny in T-inductive conditions. IL-7Rα+ 
progenitors from Hes1-deficient FL never generated expanded myeloid progeny in T-
inductive conditions (unless myeloid cytokines were provided). In fact the amount of 
myeloid progeny generated by Hes1-deficient IL-7Rα+ progenitors was reduced, likely 
due to apoptosis of these cells in T-inductive conditions.   Our in vivo studies using 
mixed FL chimeras revealed that the contribution of Hes1-deficient FL to thymic 
granulocyte chimerism was drastically reduced relative to ETP chimerism. Thus, we 
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believe that IL-7α+ progenitors much more closely recapitulated our in vivo chimera data 
than  IL-7α– progenitors.  Notably, despite the fact that the consequences of Hes1-
deficiency differed between IL-7α+ and IL-7α– progenitors, defective T cell development 
from either population could restored by Cebpa deletion. These data indicate that even 
IL-7Rα+ require constraint of C/EBPα-dependent myeloid programs by Hes1, even 
though they have attenuated myeloid potential and a higher threshold for diversion to 
myeloid fates compared to their IL-7α– counterparts. 
 
5.2.2  Thymic granulocytes are generated predominantly from Hes1-
dependent ETP/DN2 thymocytes, unlike many other alternative lineage cells 
in the thymus. 
 
 Our data indicate that although ETPs possess many alternative lineage potentials, 
they are the major precursors for only a select subset of these lineages in the thymus. 
Among alternative lineage cells in the thymus, we find that only granulocytes derive 
predominantly from ETPs. BM granulocyte progenitors or mature granulocytes 
generated outside the thymus do not appear to efficiently contribute to thymic 
granulocytes, perhaps because they lack the ability to traffic to the thymus or due to the 
short half life of granulocytes. Our results suggest that despite the demonstrated 
macrophage and B cell potential of ETPs, the major fraction of these thymic lineages 
develop independently of ETPs64,88. Hence, ETPs may contribute to lineages in the 
thymus besides granulocytes, but there are likely to be more efficient or abundant 
precursors for these cells than ETPs. 
 
 Our data, generated using multiple complementary in vivo approaches, indicate 
that thymic granulocytes have a distinct origin from peripheral granulocytes and suggest 
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a close developmental relationship with T cell progenitors for the following reasons: 1) 
thymic granulocytes are labeled by a history of RAG-1 expression in adult mice; 2) they 
are diminished in the absence of chemokine receptors necessary for thymic settling by T 
cell progenitors; 3) they rely on IL-7Rα, common γ-chain, and Hes1 for their 
development.  These properties together provide strong evidence that thymic 
granulocytes and T cells derive from the same precursors. It is important to note that 
most of our data were obtained in adult mice.  ETPs from fetal and neonatal mice retain 
different degrees of myeloid and B cell potential compared to adult ETPs98,149, which is 
consistent with our finding that neonatal thymic granulocytes are mostly unlabeled by a 
history of RAG-1 expression. 
 
The nearly absolute requirement for Hes1 in thymic granulocyte development 
confirms that thymic granulocytes develop from T cell precursors that have expressed 
Hes1 downstream of Notch signaling, at least initially. The thymic granulocyte defect in 
the absence of Hes1 is much greater in magnitude than the defect in ETPs, and is more 
similar to the defect in DN2 thymocytes. These data suggest to us that thymic 
granulocytes differentiate from ETPs as they transition to the DN2 stage. This is 
interesting to consider, because progenitors experience non-uniform levels of Notch 
ligands after entering the thymus. It has been suggested that TSPs that escape Notch 
signaling altogether might be those that generate thymic granulocytes. This may indeed 
occur; however, such cells (i.e. TSPs which have not yet upregulated Hes1 expression) do 
not appear to be the major precursor of thymic granulocytes.  
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5.2.3 Hes1-dependent ETPs (those which generate thymic granulocytes in 
vivo) are responsible for most T cell development. 
 
Our results are consistent with a model in which Notch signaling upregulates 
Hes1 expression in progenitors shortly after thymic entry, coincident with the generation 
of the ETP population.  In competitive chimeras, the absence of Hes1 resulted in reduced 
ETP chimerism, and this defect became very pronounced by the DN2 stage83,97,158. 
Consistently, Cebpa expression is sharply downregulated in wild-type progenitors by the 
DN2 stage of T cell development, suggesting that Hes1 may inhibit Cebpa expression 
during the ETP-to-DN2 transition.  
 
The ETP compartment may be heterogeneous with regard to Hes1 expression, 
since the development of some, but not all ETPs appear to be Hes1-dependent.  It is 
tempting to speculate that “Hes1-independent ETPs” are those TSPs that have a 
restricted ability to access myeloid programs, and thus do not require Hes1 for their 
development. It appears that these “Hes1-independent ETPs” cannot effectively compete 
with host ETPs in a competitive situation. In any case, it is clear that T cell development 
is severely compromised in the absence of Hes1-dependent ETPs, and that these cells are 
bona-fide myelo-lymphoid progenitors, since these are the cells within the ETP 
population that generate myeloid granulocytes in vivo.  
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5.2.4  Distinct mechanisms inhibit myeloid programs in periphery (Hes1-
independent) versus thymus (Hes1-dependent).  
 
Lymphoid specification and the attenuation of myeloid potential begins in the 
BM or FL, and is likely mediated by E-proteins, such as E2A, in collaboration with other 
transcription factors such as PU.1, Ikaros, and Gfi-149,37. E2A appears to influence 
myeloid versus lineage decisions in the BM, since residual LMPPs remaining in E2A-
deficient mice demonstrate enhanced myeloid cloning efficiency and deregulation of 
many lymphoid genes37. We hypothesize that following the initial attenuation of myeloid 
potential in early BM progenitors, lineage-specific mechanisms take over to silence 
myeloid fates in downstream progenitors as they commit to a particular lymphoid 
lineage (as discussed in the next section).  
 
Our data suggest that Hes1 constrains myeloid gene expression programs during 
intrathymic T cell development, but not peripherally during generation of BM lymphoid 
progenitors or B cells. Flt3+ IL-7Rα+ lymphoid progenitors and B cells are generated 
normally in FL and BM in the absence of Hes1. Furthermore, we did not observe 
expansion of myeloid cells/DCs from Hes1-deficient FL in the spleens of mixed 
chimeras97. Hes1-deficient FL lymphoid progenitors expressed attenuated levels of 
Cebpa compared to upstream MPPs and hence are comparable to wild-type lymphoid 
progenitors. Consistent with the idea that distinct mechanism inhibit myeloid programs 
in the thymus, versus the BM, the Cebpa locus acquires H3K27me3 repressive chromatin 
marks in ETPs that are absent in BM progenitors22.  
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5.2.5  Lineage-specific mechanisms to inhibit myeloid potential likely exist, 
since ILC2s, which use many elements of the core T cell program (TCF-1, 
GATA-3) develop independently of Hes1. 
 
Our lab has found that lung type 2 innate lymphoid cells (ILC2s) express many 
elements of the core T cell program, such as TCF-1, Gata3, and Bcl-11b, as well as the 
Notch target genes Hes1 and Deltex1 (ref. 161).  Given the close resemblance between ILCs 
and thymocyte progenitors, we are very interested in understanding the common and 
distinct elements of the ILC and T cell programs. Notch signaling clearly plays a key role 
in the development of T lymphocytes; however, its role in ILC development is much 
more ambiguous. Notch ligands promote ILC2 development from CLPs in vitro when 
OP9-DL1 stromal cell cultures are supplemented with IL-7 and IL-33 (ref. 60). However, 
it is much less clear whether Notch is required for ILC2 development in vivo, since 
different experimental models have yielded discordant results.  Retroviral expression of 
dominant-negative Mastermind like-1 (dnMAML), a pan-Notch inhibitor80 inhibits ILC2 
development in vivo161. In this system, the Notch requirement for ILC2 development can 
be partially bypassed by ectopic expression of TCF-1, indicating that TCF-1 may function 
downstream of Notch in ILC2 development161. However, RBP-Jk deletion in BM 
progenitors using the inducible MxCre did not appear to perturb ILC2 development in 
vivo60. 
 
In order to examine the role of Notch signaling in ILC2 development, we 
examined their dependence on Hes1 in mixed FL chimeras. In contrast to T cells, ILC2 
develop in a Hes1-independent manner161. Since we have found that Hes1 constrains 
myeloid programs during T cell development, we conclude that Hes1 does not serve this 
function in ILC progenitors, and that ILC-specific mechanisms likely exist to inhibit 
myeloid gene expression.  We think that examining whether Hes1 is required for ILC2 
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function and for the development of other ILC subgroups is a worthwhile area for future 
investigation. 
 
5.2.6  Multiple mechanisms exist to constrain different lineage potentials in 
uncommitted, intrathymic T cell progenitors. Protracted access to myeloid 
gene expression programs may reflect an association between these 
programs and stem/progenitor programs that drive robust T cell progenitor 
expansion. 
 
Notch signaling antagonizes multiple alternative lineage potentials, including B 
cell and myeloid fates. B lineage potential is extinguished very early in T cell 
development, and hence, B potential is only detected in a small fraction of the most 
primitive (Flt3+) ETPs found in the adult thymus67. Nevertheless, most ETPs and even 
some DN2a cells retain the ability to develop into myeloid lineage cells if removed from 
constraining Notch signals64,65. Thus, myeloid potential is clearly retained longer than B 
cell potential in the adult thymus. We have found that Hes1 is necessary for the 
inhibition of myeloid, but not B cell programs downstream of Notch signals. Other 
mechanisms, such as TCF-1 and GATA-3, likely inhibit B cell potential in progenitors 
lacking Hes191,92.   Whereas, TCF-1 is a potent inhibitor of B cell development, it appears 
to have little effect on myeloid development92. Therefore, multiple distinct mechanisms 
downstream of Notch cooperate to mediate suppression of alternative fates. Consistent 
with the idea that multiple distinct mechanisms act together to inhibit alternative lineage 
gene expression programs, analysis of sequential T cell progenitor populations by ChIP 
and deep sequencing has revealed that diverse histone modifications mark different 
genes encoding hematopoietic regulatory molecules across development22. Our 
observations provide a framework to explain the sequential loss of non-T cell potentials 
during early T cell development. It is interesting to consider why and how a system using 
distinct mechanisms to constrain different alternative lineage cell fates evolved in the 
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thymus, as opposed to a single mechanism that represses all but the T cell fate. The 
existence of distinct modules downstream of Notch signaling suggests the possibility that 
these modules are also used elsewhere. Indeed, Hes1 is known to repress C/EBPα in 
multiple cell lineages with diverse developmental outcomes130,131.  
 
The biological significance of the protracted maintenance of myeloid potential 
relative to rapid loss of B cell potential in the thymus is unclear. Perhaps the need to shut 
down the B cell program is more “urgent”, since the thymic microenvironment is rich in 
IL-7 and relatively poor in myeloid-promoting cytokines. Indeed, Notch only inhibits B 
cell development from uncommitted precursors. Indeed, committed B cell progenitors or 
B cells can overtake the thymus in the absence of T cell development, as occurs in the 
context of Notch-deficiency72.  
 
On the other hand it is possible that myeloid genes remain accessible due to the 
expression of “legacy” stem/progenitor genes, which confer uncommitted intrathymic T 
cell progenitors with robust proliferative potential87.  Examples of stem/progenitor genes 
expressed in uncommitted T cell progenitors (ETPs and DN2a thymocytes) include87: 
Lmo2 (ref. 137), Gata2, Mef2c (ref. 195), Meis1, Hoxa9 (ref. 196), Tal1, Lyl-1 (ref. 42), Sfpi1 
(ref. 190), Bcl11a (ref. 197), Hhex, and Erg (ref. 198). Many of these stem/progenitor 
“legacy” genes have described roles during the earliest stages of T cell development and 
are all shut down by B-selection. Failure to silence these “legacy” genes may result in 
leukemic transformation199.  
 
 A related idea, referred to as the “myeloid-based model” speculates that T cell 
specification (as well as B cell specification) proceeds according to a “prototypical” 
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developmental program that was once used to construct myeloid cells preceding the 
evolution of lymphocytes200.  Thus, in order to make lymphoid cells, “specialized 
machinery” such as somatically diversified antigen receptors was overlaid on the basic 
myeloid “chassis”, which provided basic elements needed for immune cell function, such 
as mobility.  According to this model, myeloid potential is maintained through several 
stages of development after early BM hematopoietic progenitors begin to differentiate 
down a lymphoid pathway. The finding that enforced expression of C/EBPα in lymphoid 
progenitors can cause reprogramming to macrophage/DC fates highlights the “close” 
relationship between myeloid and lymphoid cells178,201. Intriguingly, this property 
appears to be asymmetric, since myeloid cell types have not yet been reprogrammed to 
lymphoid fates, perhaps reflecting the increased complexity of lymphoid specification 
programs35. 
 
Following thymic entry, progenitors are thought to reside in the ETP/DN1 
compartment for as long as 10 days before progressing to the DN2 stage176. Despite the 
fact that progenitors spend roughly half their average thymus residence time in the DN1-
DN2 stage, the key developmental processes occurring during this stage remain 
relatively obscure. DN1 progenitors are estimated to divide about 10 times over this 
period, representing approximately a 1000-fold expansion in number176. Computational 
modeling studies validated using in vitro experiments have suggested that 
differentiation of DN1 cells to the DN2 stage is initially suppressed, and that the 
probability of progression to the DN2 stage increases in a cell-intrinsic manner as cells 
divide176. It is tempting to speculate as to why proliferation might cause cells to become 
eligible to proceed to the DN2 stage. One fascinating idea is that particular factors that 
inhibit differentiation need to be diluted out with each cell cycle. For example, perhaps 
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myeloid factors, such as C/EBPα, inhibit T cell differentiation. Consistently, ETPs with 
higher C/EBPα expression (as identified in a reporter mouse strain) are less efficient 
progenitor cells of T cells than are those with lower C/EBPα expression179. Hes1-
mediated transcriptional repression may be one of several mechanisms used to shut 
down myeloid gene expression. It is possible that myeloid transcription factors or Notch 
inhibitor factors (i.e. Numb202) are segregated asymmetrically in dividing ETPs, resulting 
in the formation of thymic granulocytes. In this way, development of thymic 
granulocytes from ETPs could indirectly facilitate T cell development by diluting out 
myeloid transcription factors that would otherwise inhibit T-lineage specification.  
 
Differences in the myeloid potential of ETPs between neonates and young adult 
mice support the idea that thymus settling progenitors (TSPs) vary across ontogeny, such 
that adult TSPs retain a greater degree of myeloid potential98. It is worth noting that that 
fetal and adult intrathymic progenitors differ significantly in their proliferative capacity. 
In adults, ETPs can take 10 days to reach the DN2 stage (compared to little over a day for 
fetal progenitors), and two weeks to generate DP thymocytes (compared to four days for 
fetal mice)99,100. During adult T cell development, the extended time course over which T 
cell development occurs corresponds to much more extensive proliferation of 
progenitors. Thus, it is possible that the myeloid potential of adult ETPs extends the time 
course of T cell development by antagonizing the onset of T cell specification and 
commitment. Thus, extended maintenance of myeloid programs in adult T cell 
progenitors may confer them with enhanced proliferative capacity, to meet increased 
demand for T cells in the adult organism. 
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5.2.7  Failure to inhibit myeloid programs in the absence of Hes1 causes 
defective in vivo T cell development from physiological TSPs. Cebpa 
deletion rescues Hes1 T cell developmental defect from both lymphoid 
progenitors and multipotent progenitors in vitro. 
 
 
We found that deletion of C/EBPα in Hes1-deficient progenitor cells restored all 
stages of in vivo T cell development from physiological thymus settling progenitors 
(TSPs) to wild-type levels in mixed chimeras. Hence, our results establish that the major, 
and perhaps only, role of Hes1 in hematopoietic cells during T lymphopoiesis is to inhibit 
myeloid gene expression programs.  The consequences of Hes1-deficiency differed 
between MPPs, which diverted to myeloid fates in T-inductive conditions, and lymphoid 
progenitors, which literally “would rather die” than adopt myeloid fates in T-inductive 
conditions; however, deletion of C/EBPα restored T cell development from both cell 
types. These data indicate that failure to constrain myeloid lineage gene expression 
inhibits T cell development even in the absence of overt diversion to the myeloid lineage. 
Thus, our data highlight the critical importance of constraining myeloid gene expression 
programs in intrathymic T cell progenitors.   
 
5.3  Future directions 
 
5.3.1  Further elucidation of Hes1 mechanism of repression 
 
Cebpa expression begins to be downregulated in FL and BM lymphoid 
progenitors compared to MPPs, and this likely occurs independently of Notch signaling 
and Hes1. Upon progenitor entry into the thymus, Notch signaling upregulates 
expression of Hes1 in ETPs, which mediates intrathymic repression of Cebpa. In ETPs, 
the Cebpa locus acquires H3K27me3 repressive chromatin marks that are absent in BM 
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progenitors22. Subsequently, at the DN2 stage, Cebpa mRNA is sharply downregulated 
compared to Cebpa mRNA levels in ETPs. We propose to test whether Hes1 expression is 
necessary for the deposition of repressive chromatin marks on the Cebpa locus in 
thymocyte progenitors. Furthermore, it remains to be tested whether Hes1-mediated 
Cebpa repression requires Ezh2, a member of the Polycomb Repressive Complex (PRC) 
that is necessary for deposition of H3K27me3 chromatin modifications. To our 
knowledge, Hes1 has not been previously been shown to function in cooperation with the 
PRC. 
 
5.3.2  How is myeloid silencing maintained in committed T-lineage cells? 
 
Notch signaling and Hes1 expression terminate after the DN3 stage, when TCR 
rearrangement begins to yield functional signaling receptors that subsequently regulate 
proliferation and differentiation of developing T cells. Indeed, Hes1 is important only 
prior to T-lineage commitment, since deletion of Hes1 in DN3 and DN4 progenitors with 
Lck Cre or CD4 Cre did not impair T cell development or thymic size158.  The absence of 
Hes1 expression in DP thymocytes suggests that other mechanisms may be needed to 
maintain silencing of myeloid programs in committed T cell progenitors. In contrast to 
Hes1, TCF-1 and Bcl-11b continue to be expressed beyond the DN3 stage, and thus 
represent potential mechanisms to maintain Cebpa silencing following T-lineage 
commitment. Bcl-11b expression has been shown to be sufficient to inhibit Cebpa 
expression in BM progenitors95,96. The ability of TCF-1 to inhibit myeloid potential 
appears to be much less robust than that of Hes1 (De Obaldia ME, unpublished 
observations). It is tempting to speculate that Hes1 may potently inhibit myeloid gene 
expression at the earliest stages of T cell development, to allow for ETP generation, and 
that TCF-1 would thereafter maintain this repression or perhaps further inhibit residual 
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expression of myeloid genes. Consistently, we observed in preliminary work that 
Hes1/TCF-1 double-deficient lymphoid progenitors generate Mac1+CD11c+Gr-1lo progeny 
in T-inductive conditions, whereas Hes1-deficient progenitors never did so without 
provision of myeloid cytokines. More work is needed to address the possibility that 
myeloid fate restriction is “handed off” between T-lineage factors during T cell 
development.  
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5.3.3  Clarifying the role of Hes1 in T-ALL 
 
Mutations causing constitutive activation of Notch signaling are implicated in 
more than 50% of human T cell acute lymphoblastic leukemia (T-ALL) cases203,204.  
Ectopic expression of the Notch intracellular domain (ICN) in BM progenitors induces T-
ALL204. Interestingly, Hes1-deficient cells are resistant to induction of T-ALL by ICN, and 
continuous Hes1 signals are required to maintain Notch-induced T-ALL158. Moreover, 
Hes1 may contribute to human myeloid malignancies via C/EBPα suppression205.  
 
At this time, it is unknown whether similar mechanisms downstream of Hes1 
operate during the processes of T cell development and the induction or maintenance of 
T-ALL. A distinct form of T-ALL has been identified in mice and humans, called ETP-
ALL, which resembles AML more closely than other forms of T-ALL. ETP-ALLs express 
many genes expressed by uncommitted thymocyte progenitors (Kit, Cebpa, Sfpi1, Lyl1, 
Lmo2, etc.) and have frequent mutations in cytokine receptors, such as Flt3 and IL-7Rα, 
but generally lack activating Notch mutations206,129,207.  It appears that ETP-ALL is 
characterized by initiation of the T cell program, despite the failure to silence 
stem/progenitor genes active during early T cell development, such as Lmo2. Studies of 
ETP-ALL suggest that human T cell development, like adult mouse T cell development 
occurs from progenitors with both T and myeloid potential208. Thus, understanding early 
lineage commitment events in normal T cell progenitors may shed light on mechanisms 
driving ETP-ALL.  
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CHAPTER 6:  METHODS 
 
6.1 Mice 
 
Female C57BL/6 (CD45.2+) and B6.Ly5.2 (CD45.1+) mice were purchased from 
the National Cancer Institute and were used at 5-8 weeks of age.  RAG-1/Cre mice137 
were obtained from Terry Rabbitts and bred to Rosa26-YFP reporter mice. CCR7–/–, IL-
7Rα–/–, and Cebpafl/fl mice141,193,209 were obtained from Jackson Laboratories. 
CCR9−/− mice210 were a gift of Dr Paul Love (NIH, Bethesda, MD). CCR7–/–CCR9–/–mice 
were generated by inter-crossing single knockout mice.  Mice with the Hes1-deficient 
allele were provided by Lori Raetzman (University of Illinois at Urbana-Champaign) 
with the permission of Ryoichiro Kageyama (Kyoto University Institute for Virus 
Research). Hes1–/– mice were crossed with C57BL/6 mice for about 5 generations, after 
which point further backcrossing appeared to abrogate survival of Hes1-deficient 
embryos past embryonic day 8-10. To obtain FL, embryos were generated from timed 
matings. Detection of the vaginal plug was designated E0.5. All animal experiments were 
done according to protocols approved by the Office of Regulatory Affairs of the Perelman 
School of Medicine at the University of Pennsylvania (Philadelphia, Pennsylvania) in 
accordance with guidelines set forth by the National Institutes of Health.  
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6.2 Flow cytometry and cell sorting 
 
Bone marrow cells were obtained from mouse femurs and red blood cells were 
lysed using ammonium chloride–potassium bicarbonate (ACK) lysis buffer. Fetal liver 
cells were obtained from day 12.5-16.5 embryos and red blood cells were lysed. Prior to 
cell sorting, BM underwent depletion with antibody to CD19 (anti-CD19) (1D3; BioXCell) 
and anti-Gr-1 (8C5; BioXCell) by removal of antibody-bound cells with magnetic beads 
conjugated to antibody to rat immunoglobulin G (IgG) (310107; Qiagen). Prior to cell 
sorting, thymocyte cell suspensions were depleted using anti-CD4 (GK1.5), anti CD8α 
(53.6-7), and magnetic beads conjugated to goat anti-rat IgG.  
 
Bone marrow, thymocyte and FL cell suspensions were stained with optimized 
dilutions of directly conjugated fluorescent antibodies. In most experiments, the lineage 
(Lin) antibody 'cocktail' used included anti-B220 (RA3-6B3; eBioscience) and CD19 
(1D3; eBioscience) for the exclusion of B lineage cells; anti-CD11b (anti-Mac-1; M1/70; 
BD Pharmingen) and anti-Gr-1 (8C5; BioLegend) for the exclusion of myeloid cells; anti-
CD11c (N418; eBioscience) for the exclusion of dendritic cells, anti-Ter119 (TER119; 
eBioscience) for the exclusion of erythroid cells; anti-NK1.1 (PK136; BD Pharmingen) for 
the exclusion of natural killer cells; and anti-CD3e (2C11; eBioscience), anti-CD8α (53-
6.72; eBioscience), anti-CD8b (H35-17.2; eBioscience), anti-TCRb (H57; eBioscience) 
and anti-TCRgd (GL-3; eBioscience ) for exclusion of the T cell lineage. For FL 
experiments, anti-CD11b (anti-Mac-1) was not included in the lineage 'cocktail'. 
Additional antibodies used include: anti-CD45.1 (A20; eBioscience ), anti-CD45.2 (104; 
eBioscience), anti-Kit (2B8; eBioscience), anti-Sca-1 (D7; eBioscience), anti-Flt3, anti- 
Thy1 (53-2.1; BD Pharmingen), anti-CD25 (PC61.5; eBioscience). All of the antibodies 
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noted above were directly conjugated to fluorescein isothiocyanate, phycoerythrin, 
allophycocyanin or biotin. Biotin-conjugated antibodies were visualized with either 
peridinine chlorophyll protein–cyanine 5.5–streptavidin (BD Biosciences) or 
streptavidin–Pacific blue (Molecular Probes).  
 
Cells were analyzed on a two-laser FACSCanto or a four-laser LSR II (Becton 
Dickinson). DAPI (4,6-diamidino-2-phenylindole) was used for exclusion of dead cells. 
Cells were sorted on a FACSAria (BD). Data were analyzed with FlowJo software, version 
8.8.6 (TreeStar). Progenitor populations were gated as published83. FL multipotent 
progenitor cells were sorted as Lin–Kit+Flt3+IL-7Rα– cells. FL lymphoid progenitor cells 
were sorted as Lin–Kit+Flt3+IL-7Rα+ cells. The BM LSK population was sorted as Lin–
Sca-1+Kit+ cells. BM LMPPs were sorted as Lin–Sca-1+Kit+Flt3+ cells. Thymocyte 
populations were defined and sorted as ETPs (Lin–Kit+CD25– or Lin–Kit+CD25–), DN2 
cells (Lin–Kit+CD25+ or Lin–Kit+CD25+), DN3 cells (Lin–Kit–CD25+ or Lin–Kit+CD25+) or 
double-positive cells (CD4+CD8+, CD4+ SP: CD4+CD8–,CD8+ SP: CD4–CD8+). 
 
6.3  Intravenous transfers and intrathymic transfers 
 
For intravenous transfers, female CD45.1+ host mice were lethally irradiated with 
9 Gray (Gy) and transplanted with a total of 106 bone marrow cells. Prior to 
transplantation, BM was depleted using anti-CD4 (GK1.5), anti CD8α (53.6-7), and 
magnetic beads conjugated to goat anti-rat IgG. Donor reconstitution was analyzed 8-10 
weeks post-transplant, to allow for reconstitution of the ETP compartment. For 
intrathymic transfers, female CD45.1+ host mice were irradiated with 6 Gy. Intrathymic 
transfers were done as described211. Briefly, mice were anesthetized and a thoracic 
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incision was made to expose the thymus. Freshly sorted thymocyte progenitors were 
injected directly into the thymus in a 10µL total volume.  
 
6.4  Stromal cell co-culture 
 
OP9 and OP9-DL4 cells were used essentially as described92. For most cultures, 
IL-7 was added at a final concentration of 1 ng/ml and Flt3L was added at a final 
concentration of 5 ng/ml. Stromal cell cultures were not supplemented with myeloid 
cytokines except where specifically noted. Myeloid cytokine conditions212 were as follows: 
25 ng/mL SCF, 25 ng/mL Flt3L, 5 ng/mL IL-3, 5 ng/mL M-CSF, 5 ng/mL GM-CSF and 
10 ng/mL G-CSF. To ensure adequate cytokine for B cell development, some cultures 
included IL-7 at a final concentration of 5 ng/ml. For flow cytometry, cells in 24-well 
plates were resuspended in a final volume of 300 ul and were analyzed on the cytometer 
for 30–60 s, which allowed a fraction of the well to be analyzed. Cell numbers per well 
reflect the number of events collected during a given collection time, to allow comparison 
between wells. All stromal cell co-cultures were plated in triplicate wells. Stromal cells 
were plated 2 d before initiation of culture at a density of 20,000 cells per ml in 24-well 
plates for bulk cultures or 96-well plates for limiting-dilution analysis (LDA).  
 
For LDA cultures, wells in which more than 1% of CD45+ cells were Mac-1+Gr-1+ 
or Thy1+CD25+, respectively, were considered 'positive', and all other wells were 
considered 'negative.' For each condition of the LDA 8-12 wells were examined. The 
progenitor frequency was calculated by the method of maximum likelihood applied to 
Poisson distribution with the help of the L-Calc software (StemCell Technologies). For 
LDA of transduced progenitor cells, the number of cells plated per well reflects the 
number of live transduced cells per well 6 h after plating. 
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6.5  Annexin Staining 
 
Cells were stained with annexin V according to the manufacturer instructions 
(BD Biosciences). After cell surfaces were stained, cells were washed in PBS and 
resuspended in 1× annexin binding buffer containing phycoerythrin-conjugated Annexin 
V. After 15 min of incubation at room temperature, cells were diluted in 1× Annexin V 
binding buffer and analyzed by flow cytometry. 
 
6.6  Retroviral transduction 
 
Sorted progenitor cells were transduced with retroviral supernatants in 
stimulation 'cocktail' containing 5 ng/ml IL-3, IL-6 and Flt3L, 50-100 ng/ml SCF, and 
polybrene. Progenitors were centrifuged with retrovirus/stimulation cocktail at 2,300 
r.p.m. for 2 h at room temperature and returned to a 37° C incubator. After 24–48 h, 
cells were plated onto OP9 or OP9-DL4 stromal cell layers, after being sorted as GFP+ 
cells where needed. 
 
6.7  Hes1 mutant constructs 
 
Hes1 constructs in an empty mouse stem cell virus (MSCV)-based retroviral 
vector were obtained from P. Zweidler-McKay. The Hes1 mutant lacking DNA binding 
contained substitution of alanine for three residues (Glu43, Lys44 and Arg47) in the 
basic region of Hes1 responsible for DNA binding. The Hes1 mutant lacking the 
Groucho-interaction region featured substitution of the carboxy-terminal WRPW 
domain to with Gly-Phe-Pro-Gly (GFPG)191. Confirmation that wild-type and mutant 
forms of Hes1 protein were expressed was achieved by retroviral transduction of 3T3 
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fibroblasts and intracellular staining for Hes1 (Figure 4-3). Hes1 protein was detected 
with rabbit polyclonal antibody to Hes1 (sc-25392; Santa Cruz Biotechnology) and a goat 
anti-rabbit F(ab’)2 fragment of IgG conjugated to Alexa Fluor 647 (A21244; Invitrogen). 
 
6.8  Chromatin Immunoprecipitation (ChIP) Assay 
 
Putative Hes1-binding sites were identified in the Cebpa promoter with the 
evolutionarily conserved region (ECR) browser. Thymi from mice deficient in 
recombination-activating gene 1  (RAG-1) were used for ChIP, as thymus of this genotype 
is enriched for DN3 thymocytes that express Hes1. Cells were fixed for 10 min at room 
temperature in 1% formaldehyde and were treated with 125 mM glycine. The crosslinked 
chromatin was lysed with 1% SDS lysis buffer and sheared by sonication, which produced 
fragments of 200–800 base pairs in length. Sheared chromatin was immunoprecipitated 
with 2 ug anti-Hes1 (sc-25392; Santa Cruz Biotechnology) or rabbit IgG (control 
antibody) (sc-3888; Santa Cruz Biotechnology). After samples were washed, bound 
chromatin was eluted and treated to reverse crosslinking. After treatment with RNaseA 
and proteinase K, DNA was purified with a PCR purification kit (Qiagen) and was 
analyzed by quantitative PCR. The primer sets used amplify genomic fragments 
containing two conserved Hes1-binding sites in the Cebpa promoter were as follows: site 
165 base pairs upstream of the transcriptional start site: forward, 
TTGCAGCGCAGGAGTCAGT, and reverse, ATGGTGCCTGCTGGGTCTTA; site 1.2 
kilobases upstream of the transcriptional start site: forward, 
CGGCTGTGGGTAGGAGTTTG, and reverse, GACGAAAGGCCTCAGCTCAA. Nanog 
negative control primers were as follows: forward, 5’-GGCTGCCTCTCCTCGCCCT-3’, and 
reverse, 5’-GTGCACACAGCTGGGCCTGA-3’. Hes1 promoter: forward, 5’-
CGTGTCTCTTCCTCCCATTG-3’, and reverse, 5’-CCAGGACCAAGGAGAGAGGT-3’.  
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6.9  Luciferase assay 
 
The Cebpa promoter reporter construct was made by cloning of about 1 kilobase 
of sequence upstream of the Cebpa transcriptional start site, which encodes one Hes1-
binding element, upstream of the minimal SV40 promoter in the pGL3-promoter 
reporter vector (Promega). 293T cells were seeded 1 d before transfection to reach 80% 
confluency, then were transiently cotransfected through the use of LipoD293 reagent 
according to the manufacturer's protocol (Stratagene). The total amount of DNA was the 
same between all wells, and constructs were used in the following amounts: Promega 
pGL3 promoter vector, 300 ng per well; vector encoding Hes1-GFP or empty vector, 300 
ng per well; and renilla luciferase, 50 ng per well). DMEM containing 10% L-glutamine 
and 10% penicillin-streptomycin was added 12 h after transfection, and cells were 
harvested 24 h after transfection and analyzed with a Dual Assay Reporter kit (Promega) 
and GloMax 96 Microplate luminometer (Promega). Results were analyzed by 
comparison of firefly luciferase activity to renilla luciferase activity and were normalized 
to reflect the increase over background. We verified that Hes1 expression inhibited the 
activity of a positive control luciferase reporter containing the Hes1 promoter 
sequence191, but did not repress the empty Promega PGL3prom luciferase reporter, as a 
negative control (data not shown). 
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6.10  Wright-Giemsa staining 
 
Sorted populations were spun onto glass slides using a Shandon cytocentrifuge. 
Cells were fixed in fresh methanol and stained in Wright-Giemsa reagent (Fisher 
Scientific) for 3 min, followed by Wright-Giemsa with Original Azure Blend (Harleco) for 
10 min, then Wright-Giemsa with phosphate buffer pH 6.8 (Fisher Scientific) for 2 min. 
Stained slides were washed with ddH2O, allowed to dry, coverslipped, and examined 
under the microscope. Microscopy pictures shown are 100X. Equipment and software 
used include: Leica DMRBE widefield microscope, Qimaging MicroPublisher 5.0 MP 
camera, iVision for Mac acquisition software. 
 
6.11  Quantitative PCR (qPCR) 
 
For quantitative PCR, mRNA was isolated using the RNeasy Kit (Qiagen) and 
reverse transcribed with Superscript II (Invitrogen). The resultant cDNA was then 
amplified and detected with pre-made Taqman primers and probes for Dtx1, Cebpa, 
Csf1r, Hes1, Sfpi1, Gata3, Tcf7, Bcl-11b, and Cdkn1b (Applied Biosystems). A 
StepOnePlus Real-Time PCR System (Applied Biosystems) was used for amplification 
and analysis. Relative transcript abundance was determined by the change-in-cycling-
threshold (ddCt) method after normalization with the control gene Gapdh or 18S RNA.  
All samples were run in triplicate. Error bars represent SEM. 
 
6.12  Statistical analysis 
 
Each data set was analyzed using the Student’s t-test on Microsoft Excel, with a 
two-tailed distribution assuming equal sample variance. 
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